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Abstract
Two primer sets were manufactured from the cytadhesin PI gene of M. Pneumoniae 
in an attempt to amplify homologous sequences inM mycoides subsp. mycoides “SC” Type 
in a search for a PI-like gene in the latter organism. The first primer set MP-2 amplifies a 
488 bp fragment in M. pneumoniae. The second primer set MP-3 amplifies a 303 bp 
fragment bracketing the 13-amino acid binding domain in the same organism.
Both primer sets amplified the expected fragments in all the virulent strains of M. 
mycoides subsp. mycoides “SC” type. The primer sets did not however amplify the 
expected fragments in the vaccine T1 strain of the organism.
A third primer set (MP-V) was then selected from the sequence of the CAP-21 gene 
insert described by Taylor et al, 1992. This primer set amplifies a 458 bp fragment in all 
members of the M. mycoides cluster including the T1 strain. The primer set amplified the 
expected fragment in all the virulent strains as well as the T1 vaccine strain of M. mycoides 
subsp. mycoides “SC” type but did not amplify it in M. pneumoniae and M. genitalium.
A comparison of the protein pattern of the virulent strain PG1 and the vaccine T1 
strain of M. mycoides subsp. mycoides “SC” type revealed considerable protein differences.
A multiplex PCR assay was then developed to differentiate the virulent strains from 
the T1 vaccine strain of M. mycoides subsp. mycoides “SC” type using the primer sets MP- 
3 and MP-V. The assay amplified two fragments in all the virulent strains of the organism 
(the 303 bp and the 458 bp) and only one fragment (the 458 bp) in the T1 strain thereby 
differentiating the strains in one amplification procedure.
xi
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The assay was then employed to test crudely prepared field samples from cattle 
suspected of CBPP infection but previously vaccinated with the T1 strain.
xii
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Chapter 1. Contagious Bovine Pleuropneumonia: The Disease and the Etiological
Agent in Somalia
Introduction:
The disease contagious bovine pleuropneumonia (CBPP) is an infectious disease 
caused by Mycoplasma mycoides subspecies mycoides “small colony (SC)” type and is 
endemic in many parts of the world. It particularly poses serious socioeconomic problems 
in subsahara Africa. In Somalia, where the economy is dependent on the export of live 
animals, CBPP has had great impact on the overall economy of the country because of trade 
bans. These trade bans came as a result of serologically detecting antibodies against the 
etiologic agent or microbiologically isolating it. Since Somali cattle are vaccinated before 
shipment, it has been and continues to be a problem differentiating vaccinal antibodies from 
natural infection antibodies. It has also been impossible with the available diagnostic 
procedures in Somalia to differentiate the virulent strains of the etiologic agent from the 
vaccine T1 strain which is used in Somalia to vaccinate cattle against CBPP. A solution to 
either one of these problems could significantly stabilize the economy by laying a solid 
foundation against bans when antibodies detected in the export cattle can be ascribed to the 
vaccine strain T1 or an isolated agent can be proven not to be the virulent strain.
The vaccine strain was derived from the virulent strain by serial passaging, therefore 
it appeared reasonable to use molecular biology techniques to differentiate the two strains 
at the genetic level. In addition, these differences at the molecular level could potentially 
answer some of the unknown aspects of the disease and the etiologic agent.
I
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2Therefore, the major objective of this research was to identify a molecular 
difference between the virulent and vaccine strains and to exploit this difference to develop 
an epidemiologic tool for strain differentiation in field specimens. This research was also 
initiated to provide a tool which may be useful to identify CBPP infections in field samples. 
Use of this tool could also provide a rational approach for reducing outbreaks due to the 
virulent strains by detecting animals that are carriers and those that are incubating the 
disease. With these goals in mind, the search for a difference between the virulent strain 
and the vaccine strain was began. Since the state of avirulence of the vaccinal T1 strain 
suggested that mutations may have occurred in one or more of the virulence genes during 
passaging, we exploited the close relationships between mycoplasmas and used sequences 
from the virulence gene PI of Mycoplasma pneumoniae to detect homologous sequences 
in M. mycoides subsp. mycoides “SC” Type. M. pneumoniae is pathogenic and has tropism 
for the human lung tissue. Besides, its PI virulence gene has homology sequences with the 
PI-like virulence genes of M. genitalium, and M. gallisepticum. Therefore, we 
hypothesized that since M. mycoides subsp. mycoides also is pathogenic and has tropism 
for the lung tissue of cattle, a gene similar to the PI gene may also exist in it.
The investigation into the possible presence of a cytadherence gene in M. mycoides 
subsp. mycoides “SC” Type is discussed in chapter two. Chapter three describes the 
development of a multiplex PCR assay for the differentiation of the virulent strains from 
the vaccine T1 strain in purified DNA and in field samples from Africa. The fourth and 
final chapter gives some guidelines on conducting investigations that require repeated 
sampling in the nomadic population of Somalia.
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3(1). To identify the presence of the “putative” cytadhesin gene of M. mycoides subsp. 
mycoides “SC”type and determine if differences in genetic sequences of this gene exist 
between the virulent and vaccine strains.
(2). To develop a multiplex PCR assay that can distinguish the virulent strains of M. 
mycoides subsp. mycoides “SC” type from the vaccine strain Tl.
(3). To characterize the PCR assay to differentiate between virulent and vaccine strains of 
M mycoides subsp. mycoides “SC” type in field specimens.
(4). To develop guidelines for sampling of nomadic populations of Somalia for potential 
use of the ppolymerase chain reaction assay for detection of CBPP infection in Somali 
cattle in particular and African cattle in general.
(5). To characterize the sensitivity and specificity of the multiplex PCR assay both in 
detecting virulent strains and also in differentiating the virulent strains from the vaccine Tl 
strain. Also characterize the specificity by using other mycoplasmas that also affect cattle 
and other wild bovids.
(6). Ascertaining the correct use of the multiplex assay in categorizing the virulent strains 
and the Tl vaccine strain so that a correct appraisal can be made about mycoplasma 
isolations in the export cattle of Somalia. This will help concince importing countries about 
isolates of mycoplasmas made in their laboratories.
(7). Establish both the epidemiological and microbiological sensitivity of the multiplex 
polymerase chain reaction assay.
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4Background and literature review:
Contagious bovine pleuropneumonia is a highly transmissible, highly contagious 
and economically important disease of Bos taurus (European cattle) and Bos indicus (zebu 
cattle) and some wild bovids (Priestley, 1960; Kamara, 1975; Abdalla, 1975; Provost, 1987; 
Paling et al, 1988). It is not known if the disease affects camelids although antibodies 
against Mycoplasma mycoides subsp. mycoides were serologically detected in llamas in 
South America where the disease has not been reported and in camels (Camelus 
dromedarius) in Africa (Hung et al, 1991; Paling et al, 1988). Generally European cattle 
are more susceptible than zebu cattle and animals over the age of two years are at an 
increased risk of contracting the disease.
The disease is endemic in the continents of Africa, Asia, Southern Europe and 
possibly Eastern Europe and the former Soviet Union (OIE-FAO, 1991; FADR, 1991; 
Prosperi et al, 1991). Mass vaccinations in Somalia and other African countries may have 
reduced the incidence of the disease but economic losses from the disease are still high 
(Provost, 1987; Kalif, 1992). One of the economic side effects of CBPP is that trade of 
livestock and its products from Africa to the rest of the world is virtually non-existent 
largely because of the fear of importing depopulating diseases such as CBPP, rinderpest, 
FMD, etc. The reduction in CBPP incidence as a result of mass vaccinations brought about 
an increase in the animal population which is not offset by offtake in export. This resulted 
in overgrazing and contributed to the desertification of Somalia.
In countries like Somalia whose economy is totally dependent on the export of live 
animals (over 80% of Somalia’s foreign earnings come from the export of livestock), trade
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
bans instituted to prevent importation of CBPP can have severe socioeconomic 
consequences. The 1983 Saudi Arabian ban of Somali cattle imports caused the total 
collapse of the Somali economy and was a large contributing factor to the civil unrest that 
begin in the north and culminated in the present anarchy. Previously Saudi Arabia had 
absorbed 70% of Somali livestock exports (MLFR, 1988-89; Kalif, 1992). The ban was 
imposed after Saudi Arabia claimed to have detected animals positive for the presence of 
CBPP and rinderpest antibodies. Both diseases are however endemic in Saudi Arabia (OIE- 
FAO, 1991). Somali cattle, especially those for export are vaccinated against both diseases 
before shipment (Kalif, 1992).
While outbreaks of CBPP are reported in Somalia in all seasons, generally, as in 
other countries, it is more frequent in the two dry seasons (January-April; August-October) 
possibly because of the high animal density at watering points along the two rivers and at 
the boreholes in the countryside and also because of the effect of poor grazing opportunities 
on the animals (Kalif. 1992; Nwanta et al, 1992). Highly morbid, the mortality rate depends 
on the season but it is not unusual to see case fatality rates (CFR) as high as 70%. In 
Somalia, there are many factors that contribute to the propagation and persistence of CBPP:
a. The cool and humid climate in the rainy seasons.
b. The constant seasonal and trade movement of cattle.
c. The enormous congregation of livestock at watering points during the dry seasons.
d. The scarcity of grazing during the dry seasons, which adversely affects the animal’s 
ability to resist pathogenic microorganisms.
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6e. The traditional small enclosures where animals are kept during the night from wandering 
out, a protection against wildlife and human predators.
f. The lack of vaccines in the inaccessible areas of the interior.
The disease has a subacute, acute and chronic forms. The latter is very important in the 
epidemiology of the disease. Under stressing conditions, chronic cases disseminate the 
causative agent while the animal shows no clinical signs, serologically tests negative, and 
can only be diagnosed at postmortem (Politz, 1976; Provost, 1987). The agent can, 
however, be recovered from the ear canal and respiratory tract of apparently healthy 
animals that have a history of natural infection (DeMassa, 1990; Masiga et al, 1973). In 
addition, the CBPP agent has been recovered from both healthy and diseased goats and 
sheep but it is not clear if this has any epidemiological significance especially in countries 
like Somalia where families rear cattle, goats, sheep and camels together (Ojo, 1987; 
Brandao, 1995; DaMassaetal, 1991; Machado et al, 1985).
CBPP is often clinically complicated and/or precipitated by other diseases such as 
hemorrhagic septicemia (HS), bovine viral disease (BVD), trypanosomiasis, etc. and 
stressing factors such as vaccinations, long seasonal or trade movements, etc (Onoviran et 
al, 1977). In an epidemic outbreak within a given herd, the disease assumes an explosive 
character at the beginning and then both morbidity and mortality rates tend to decrease. It 
was found and experimentally reproduced that organisms isolated at the end of the outbreak 
are less pathogenic than those isolated at the beginning of the outbreak (Bygrave et al, 
1968).
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7Diagnosis of the disease:
The diagnosis of CBPP is based on clinical and postmortem findings and on 
microbiological and serological laboratory procedures. In countries where the disease is 
endemic, the clinical and postmortem picture is sufficient for a diagnosis although the 
clinical picture is less defined in the mild form of the disease where the classical symptoms 
are sometimes not clearly manifested (Kalif, 1992). The microbiological diagnosis of the 
disease requires isolation of the etiologic agent which is difficult, tedious, and costly both 
in time and money (Gaillard-Perrin et al, 1987). As a consequence, various serological tests 
have been developed and extensively used in the diagnosis of the disease (Campbell et al, 
1953; Lindley, 1958; Cottew, 1960; Shifrine, 1967; Ladds, 1969; Onoviran et al, 1979; 
Provost, 1987; Zhao et al, 1990). The usefulness and interpretation of these tests are 
however limited and made more difficult by non-specific and cross-reactions and by their 
lack of insensitivity to chronic carriers and animals incubating the disease (Politz, 1976; 
Etheridge et al, 1987; Kalif, 1992; Kibe et al, 1985). Besides, serological tests are not able 
to differentiate between antibodies produced as a result of vaccination and those produced 
by natural infections (Roberts et al, 1974). Such tests would be especially useful for the 
surveillance and monitoring of the disease in general and among the export cattle of 
Somalia in particular.
In light of the short-comings of the serological tests, DNA probes have been developed 
for the diagnosis of mycoplasmal diseases of other animal species (Ahrens et al, 1991; 
Hyman et al, 1989; Levisohn et al, 1989; Zhao et al, 1990; Kunita et al, 1989; Narita et al, 
1992). Although highly sensitive and highly specific, one of the limitations of these probes
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8is their need for the presence of at least 1 ng of mycoplasma DNA for detection. That 
amount of DNA corresponds to DNA of about 106 mycoplasma bacterial cells, which can 
only be found in the acute phase of the disease in the live animal when the disease is 
clinically evident (Nascimento et al, 1990). In addition it requires highly trained technicians 
to conduct it and days to perform it.
Given the problems associated with probes, Polymerase Chain Reaction (PCR) assays 
have been developed for Mycoplasma gallisepticum, a poultry pathogen, and Mycoplasma 
pneumoniae, a human pathogen (Nascimento et al, 1990; Narita et al, 1992), and for the 
agent of CBPP (Dedieu et al, 1994; Bashiruddin et al, 1994). Highly sensitive and highly 
specific, the Nascimento assay, for instance, detected 102 pg of M. gallisepticum DNA, a 
fraction of the total chromosomal content of a single mycoplasma cell (Nascimento et al, 
1990). The only drawback with PCR assays is the need to know, beforehand, part of the 
DNA sequence of the fragment to be amplified to synthesize specific primers (Saiki, 1989). 
Besides, they need skilled technicians and laboratories with the required equipment. Their 
sensitivity, specificity, and cost-effectiveness make PCR assays the best tool in diagnosing 
CBPP so that effective control measures can be instituted before an outbreak occurs. 
However, no PCR assay has ever been developed to differentiate the virulent strains from 
the vaccine strains. For that matter, no test has ever been developed for the differentiation 
of these strains.
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9Control measures in Somalia:
The country had never developed an effective control program for the disease mainly 
because of the problematic practices inherent in the nomadic form of livestock rearing. The 
policy for control had always been one of outbreak containment and vaccination of affected 
herds. The Tl vaccine broth used in Somalia (and the rest of Africa) is an effective vaccine 
that produces an immunity that lasts for about a year. However, distinguishing animals 
vaccinated against CBPP from non-vaccinated ones was not possible in Somalia since cattle 
owners dislike the idea of having their cattle ear-punched every year after each CBPP 
vaccination. With rinderpest, hemorrhagic septicemia and anthrax vaccinations also 
requiring ear-punching, the animals are subjected to ear-punching at least three times a 
year. This practice tends to mutilate the ears of the animals and thus the reluctance of the 
owners to vaccinate their herds. The Somali government also instituted a policy of 
vaccinating against CBPP and some other diseases all animals intended for export at least 
three months prior to their shipment to the Arabian countries. The policy was adopted 
simply to forestall outbreaks of these diseases during the stressful journey. Antibiotic 
treatment is prohibited for export animals within 45 days of shipment. The vaccination 
practice especially against CBPP created a furor when the importing countries detected 
antibodies against CBPP or isolated the etiological agent from the animals. Since it is 
impossible to distinguish vaccination antibodies from natural infection antibodies or 
virulent strains from the vaccine strain with the conventional tests available in Somalia at 
the time, the need arose for a rapid and simple test that can distinguish the virulent strains 
of the agent from the vaccine strains.
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10
The problem of CBPP control in Somalia is also compounded by the transhumant 
nature of the nomadic population who own more than 95% of the livestock population. 
Their seasonal movement in search of water and grazing involves not only the crossing of 
intra-regional boundaries within Somalia but also moving across international borders into 
the neighboring countries of Kenya, Ethiopia, and Djibouti and vice versa. The logistical 
problems involved in vaccine production and maintaining an effective cold chain and the 
difficult task of locating herds in constant movement in the interior of the country are just 
a few of the factors that limit mass vaccination in Somalia. The only feasible time of the 
year when one can expect to find (and be able to vaccinate) at least a majority of the cattle 
is during the two dry seasons when all animals congregate at the watering points if the 
animals can stand the stress of the season and the additional stress of being vaccinated. 
Controlling or aiming at the eradication of CBPP in one African country without a 
coordinated effort to control and eradicate it in neighboring countries is an exercise in 
futility given the transhumant nature of nomadic populations in moving across international 
borders in search of grazing and watering. This is especially true in the nomadic 
populations of East Africa and the Sahel region of West Africa.
Until the start of the civil in 1991, the country used to produce enough Tl vaccine for 
all its needs and more to sell to other countries. Sadly both the vaccine institute and its 
technical staff have been totally and completely destroyed in the civil war. Rebuilding the 
institute is going to be an expensive undertaking but one that is necessary.
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The agent: mycoplasmas in general:
Ecology;
Saprophytic and pathogenic mycoplasmas of animals, humans and plants exist in 
nature. Unculturable Mycoplasma-like organisms (MLOs) have also been isolated from 
both plants and animals including arthropods (Razin, 1992). Mycoplasmas are generally 
host specific. One of the major obstacles in controlling pathogenic mycoplasmas is the fact 
that almost all of them have no known natural reservoirs.
Taxonomy:
It is believed that mycoplasmas arose by degenerative evolution from the 
Lactobacillus-Streptococcus subgroup of gram-positive, spore forming eubacteria, losing 
their cell wall in the process (Maniloff et al, 1981). Taxonomically, mycoplasmas are 
grouped in the class Mollicutes (soft skin) of the Tenericutes (wall-less bacteria) division, 
which is one of the four divisions of the kingdom Procaryotae. They belong to the order 
Mycoplasmatales. Although distinguishable on the basis of morphology, metabolic 
properties and genome size, members of the order Mycoplasmatales are further 
differentiated on the basis of their requirement of sterol for growth; The families 
Mycoplasmataceae and Spiroplasmataceae require sterol, while the family 
Acheloplasmataceae does not (Edward et al, 1970; Whitcomb et al, 1980; Christiansen, 
1987; Pathak et al, 1988). New mycoplasmas however are being identified regularly and 
the taxonomy keeps changing. Of all the Mycoplasmas, M. neurolyticum, a mouse 
pathogen, is the only one that produces a toxin, a neurotoxin in this case.
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Structure and biochemical properties:
Generally, mycoplasmas catabolize glucose, and hydrolyze arginine and urea. They 
grow in the presence of 5% C02. They assume the classical fried-egg shape in solid media, 
while in liquid media they form filaments of various sizes (Razin et al, 1992). Their size 
ranges from 0.3-0.8 i*m in diameter (Pathak et al, 1988). They are sensitive to heat, 
sunlight, ultraviolet rays, and all common disinfectants.
Structurally, they are composed of an outer envelope (capsule), cytoplasmic 
membrane, cytoplasm and nucleus. The envelope of M. mycoides subsp. mycoides is a 
galactan (polymers of the polysaccharide galactose). The capsule polysaccharide has anti­
phagocytic properties, which allows the organisms to grow on the surfaces of macrophages 
and neutrophils without activating the phagocytic process (Maniloff, 1992). The galactan 
of M. mycoides is not immunogenic unless combined with protein macromolecules or 
Freundt's adjuvant (Maniloff, 1992). It has similarities with the pneumogalactan of cattle, 
a normal lung epithelial cell product (Maniloff, 1992). The galactan is also produced by 
other eubacteria (Diplococcuspneumoniae, Actinobacillus lingneresi, E.coli, Aeromonas, 
Corynebacterium), and plants (Maniloff, 1992). The membrane is composed of three layers: 
A lipid layer sandwiched between two protein layers. The membrane antigens are soluble.
While Mycoplasmas are sensitive to the elements when outside their hosts, they 
however possess enormous survival abilities inside the host against the host’s defence 
mechanism.
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Genome:
Mycoplasma and Ureoplasma species have genome sizes that vary from 500 bp to 
1,300 bp, while Achelopalsma and Spiroplasma have genome sizes in the range 1,350- 
1,700 bp. Mycoplasma have a circular double stranded DNA (Razin et al, 1992).
The G+C content of mycoplasma DNA falls within the range 24-33 mol%. Some 
of the adenine and cytosine residues in mycoplasma may be methylated. Bovine Group 7 
and the SC type of M. mycoides subsp. mycoides lack methylation at the GATC site while 
the LC type possesses methylation at this site (Razin et al, 1980).
The mycoplasma genome has a high A+T content with M. capricolum possessing 
the highest content (75%) (Dybvig, 1990). Generally, spacer regions between genes are 
80% A+T; protein genes are about 70% A+T; rRNA and tRNA coding regions with about 
50% A+T (Dybvig, 1990). As a result of the high A+T content, denaturation of 
mycoplasmal DNA requires higher temperatures than normally required for the 
denaturation of other bacterial DNA (Dybvig, 1990).
Mycoplasmas appear to use the codon UGA to code for tryptophan and UAA as 
a termination codon (Dybvig, 1990). The other eubacteria use UGG or TGG to code for 
tryptophan and UGA as a termination codon (Dybvig, 1990). They may also utilize UGG 
(TGG) to code for tryptophan, but because of the bias towards A+T, UGA is the preferred 
codon. These observations suggest that mycoplasmas are undergoing a selective pressure 
to replace G+C base pairs with A+T base pairs (Dybvig, 1990). This fact has been an
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obstacle in mycoplasma research in molecular cloning and expression techniques in the past 
few decades.
Motility:
Some mycoplasmas move by gliding on surfaces. Attachment to surfaces is
required for this gliding motility to occur (Maniloff, 1992). Only pathogenic mycoplasmas
(M mycoides, M. pneumoniae, M. genitalium, M. gallisepticum, M. pulmonis) have this
gliding motility characteristic. These pathogenic mycoplasmas exhibit a filamentous or
flask-shaped polarity of the cell body in light microscopy (Maniloff: 1992).
The cell polarity consists of the presence of terminal organelles or blebs. It is at 
these terminal organelles that pathogenic mycoplasmas attach to host cells (Bredt et al, 
1977; Hansen et al, 1979,1980; Krause et al, 1982, 1983). The terminal organelles or blebs 
are composed of proteins. Some of these have been isolated and their sequence determined 
(Su et al, 1987; Inamine et al, 1989; Dallo et al, 1989).
Mycoplasmas also exhibit chemotaxic and rheotaxic behaviour (KirchhofT et al,
1984; Rosengarten et al, 1988). Motility, chemotaxis and rheotaxis are thought to play a
significant role in the pathogenicity of mycoplasmas (Kirchhoff, 1992).
Virulence and pathogenicity:
For pathogenicity, mycoplasma organisms need to adhere to the epithelial cells of 
the host. Although the presence of proteins involved in cytadherance have never been 
demonstrated in the M. mycoides cluster, different densitometeric patterns were observed
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between the proteins of the virulent M. mycoides subsp. mycoides strain and the vaccinal 
strain in acrylamide gel electrophoresis (Stone et al, 1973). The mechanism by which 
attenuation occurs through passaging in the T1 strain is not known.
Cytadherance proteins were demonstrated in M. pneumoniae (Baseman et al, 1982; 
Krause et al, 1982). Mycoplasma cells that lack these proteins were not able to adhere to 
the host epithelial cells and, thus, were not pathogenic. Subsequently, the cytadhesin gene 
(PI) responsible for one of the adhesin proteins of M. pneumoniae ( the calculated 
molecular weight of the protein is 176,288 kiloDaltons) was identified and sequenced. The 
gene, PI, has 4881 nucleotides and is thought to be part of an open-reading frame (Su et 
al, 1987).
Using probes made from the cytadhesin gene (PI) of M. pneumoniae, a 
homologous sequence was detected in M. genitalium (Dallo et al, 1990). Subsequently, the 
cytadhesin gene of M. genitalium was sequenced (Dallo et al, 1989). This cytadhesin gene, 
P140, has 5335 nucleotides and codes for a protein of about 160 kDa (The calculated 
molecular weight of the protein is 159,668 kiloDaltons). Again, using at low stringency 
probes made from the cytadhesin gene PI of A/, pneumoniae, homologous sequences were 
detected in both M. genitalium and M. gallisepticum suggesting the possible presence of 
a gene similar to the PI gene of M. pneumoniae that code for virulence factors in both 
mycoplasmas. All three mycoplasmas are pathogenic and all have tropism for the lung 
tissue of their respective hosts (Dallo et al, 1990).
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A group of 13 amino acids were later identified in the PI gene of M. pneumoniae 
as the binding domain (Dallo et al, 1991). Although claims of the presence of these 13 
amino acids in the PI40 protein of M. genitalium were published by various researchers, 
a visual comparison of the published amino acid sequences of PI and PI40, does not 
support the claims. The published sequences of the PI gene of M. pneumoniae and PI 40 
of M. genitalium do, however, show areas of homology ranging from 62% to 100% (Dallo 
etal, 1991).
The etiological agent of CBPP:
The “Small Colony” type of M. mycoides subsp. mycoides is the causative agent 
of Contagious Bovine Pleuropneumonia. The “Large Colony” variant causes a complex 
disease syndrome including pleuropneumonia, mastitis and arthritis in goats (Ojo, 1987). 
Strains are usually given the names of the places from which they are isolated, e.g. the 
Gladysdale strain from Australia, Mara, Baringoni, Oremit from Africa. Each type strain 
(“LC” or “SC”) is specific for its respective host. i.e. the “LC” type is specific for goats and 
the “SC” type is specific for bovids.
Besides host preferences, the “SC” and “LC” types ofM mycoides subsp. mycoides 
differ in the quality of their protective antigens. Mice vaccinated with the LC type were not 
protected when challenged with the SC type (Smith et al, 1981). The two also differ in their 
respective genome sizes. The SC type has relatively a larger genome. The restriction 
enzyme Apal does not digest SC type DNA, while it has two restriction sites for the LC 
type DNA (Pyle et al, 1990). Protein comparisons between the virulent strains revealed no
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differences and a protein comparison between a virulent strain and the T1 vaccine strain 
reported no differences ( Stone et al, 1973). The “SC” and “LC” types also differ in the size 
of the respective colonies they form on agar.
Also the vaccine strain T1 used in Somalia and the rest of Africa is a wild strain 
attenuated through passaging and is indistinguishable from the virulent field strains in 
every respect except in pathogenicity (Brown et al, 1965).
Non-specific and cross-reactions:
While a large antigenic homology exists within the M. mycoides cluster (M 
mycoides subsp. mycoides, M. mycoides subsp. capri, M. capricolum, the F38 group, Group 
7 of Leach), the CBPP agent has some common antigens with a fairly large number of other 
cattle mycoplasmas. These common antigens account for the frequent cross reactions 
encountered in serological tests (Vardam et al, 1980; Lefevre et al, 1987; Taylor et al, 1989; 
Rose et al, 1989; Gail et al, 1983; Bereiter et al, 1990; Etheridge et al, 1986; Emo, 1987; 
Cimolai et al, 1987; Sasaki et al, 1987; Regalia et al, 1988; Leach et al, 1989; Kalif, 1992). 
Taylor et al, 1991 found that a probe made from M mycoides subsp. capri detected similar 
sequences in the M. mycoides cluster. The probe detected homologous regions in all cluster 
strains, but with considerable base differences in the sequence (Taylor et al, 1991)
Etheridge et al, 1976 discovered that other cattle mycoplasmas were responsible 
for the cross-reactions to the CBPP agent in Australia where the disease has been eradicated 
(Etheridge et al, 1976).
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Sasaki et al, 1987 found significant reactions when pooled human sera was tested 
with ELISA and suggested that cross-reactive antibodies to mycoplasma exist in human 
sera and that they affect the results of the test (Sasaki et al, 1987).
Besides cross-reactions, non-specific reactions in serological tests employed in the 
diagnosis of CBPP make their interpretation more difficult. Various reasons have been 
formulated as to the cause of non-specific reactions:
(1). Ansari et al, 1989 attributed it to the storage of serum at +4° C, freezing and thawing 
of serum, and inoculation of animals with sterile media (Ansari et al, 1989).
(2). Nicolet et al, 1980 suggested that non-specific reactions are due to components of the 
antigen (Nicolet et al, 1980).
(3). Lauerman et al, 1991 demonstrated the presence of IgG-FC receptors in Mycoplasma 
sinoviae which reacted with normal serum IgG of different animal species and suggested 
that they may be responsible for the non-specific reactions seen in the serums (Lauerman 
etal, 1991).
(4). Finally, Kalif (1992) provided evidence of the possible presence of IgG-FC receptor(s) 
in M. mycoides subsp. mycoides LC type (Kalif, 1992).
Transmission:
Transmission is principally by aerosol of nasal droplets. Urine aerosol, semen, and 
transplacental transmission have all been suggested (Volintir et al, 1971; Masiga et al, 
1972; Scudamore, 1976; Emo, 1987; Ball et al, 1987; Provost, 1987). The infective dose
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of the organism is not known but transmissions of 55 meter distance has been reported 
(Provost, 1987). The incubation period is not well defined and probably ranges from a few 
days to weeks in natural infections depending on the susceptibility of the animal, dose, and 
the state of the disease in the area. That is to say whether the area is endemic or it is an area 
where the disease appears for the first time. Experimentally the range is from 20 days to 
123 days when healthy cattle were placed in contact with infected ones (Provost, 1987).
Unknown aspects of the disease and the etiologic agent:
There are many aspects of the disease and the etiologic agent of CBPP, crucial to the 
control and eventual eradication of the disease, that are still obscure and need clarification:
It is known, for instance, that the disease affects some wild bovids (Fisher, 1986; 
Provost, 1987). Whether the same strain of the organism causes the disease in both wild and 
domestic animals is not known. If the same strain is involved, it is not known whether wild 
animals act as natural reservoirs for the agent and contaminate the sources of drinking water 
in natural depressions and borehole troughs during the night.
It is also known that the etiologic agent of CBPP has been recovered from nasal swabs 
of apparently healthy animals (Ojo, 1987). This fact has fueled suspicion that animals in 
the incubation phase of the disease shed the organism silently without showing any clinical 
symptoms. This may explain the high morbidity of the disease in outbreaks when many 
animals in the herd come down with the disease within a short period of time.
Chronic cases of the disease are virtually impossible to detect with serological tests, 
although viable organisms can be cultured from the animal. They are usually detected only
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at postmortem and are important in the epidemiology of the disease because they shed the 
organisms in all stressful events (Politz, 1976; Provost, 1987). Why these animqls do not 
have an immunological response is not known although it can be speculated that in these 
animals, the number of organisms they harbor are not numerically sufficient to provoke a 
response. Besides, the viable organisms are usually interned in lung sequestra where they 
have no contact with the host’s immune system.
Outbreaks of CBPP have been observed in animals previously vaccinated with live 
attenuated vaccines, especially when animals are infected with trypanosomiasis, 
dermatophilosis, and other immunosuppressive conditions (Chima et al, 1986; Osiyemi, 
1985; Ilemobode, 1982). Whether the vaccinal strain or the virulent “wild” strain is 
responsible for these outbreaks is the subject of a continuing debate.
Variations in the severity of the disease from one geographical area to another have 
been observed. It has also been noted that isolates from the onset of an outbreak are more 
virulent than those isolated at the end of the outbreak (Bygrave et al, 1968). Whether the 
strains are being attenuated through the animals they infect or are different strains- some 
highly virulent, others with moderate virulence and still others with low virulence involved- 
is not known.
The CBPP agent has been recovered from ticks and fleas that have, experimentally, 
transmitted the disease to susceptible animals (Shiffine et al, 1972; Nayak et al, 1990). It 
is not clear whether ticks and fleas act as vectors under normal field conditions or if they 
even act as short term reservoirs.
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Finally, presumably because of the manner in which these vaccines are derived, i.e. 
extended passaging, it has been virtually impossible to differentiate vaccinal antibodies 
from natural infection antibodies (Roberts et al, 1974). Besides, apart from virulence, the 
vaccinal strain is impossible to differentiate from the wild virulent strain on cultural and 
routine immunological tests. The differentiation between these strains is crucial for 
developing countries such as Somalia whose economy is dependent on the export of live 
animals.
These aspects of the disease and the causal agent need to be investigated and defined 
so that appropriate and meaningful control and eradication programs can be formulated and 
implemented with no hidden surprises.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Chapter 2. Presence of a “Potential” Cytadherence Gene in Mycoplasma mycoides 
subsp. mycoides “SC” Type Similar to the PI Gene in Mycoplasma pneumoniae 
and the P140 Gene in Mycoplasma genitalium 
Introduction:
Mycoplasmas are widely known to cause disease conditions in animals, humans and 
plants. In animals, the best known diseases are contagious bovine pleuropneumonia (CBPP) 
and contagious caprine pleuropneumonia (CCPP). Both diseases are endemic in Africa and 
Asia. CBPP is also endemic in Southern Europe (Provost, 1987; FADR, 1991). Both 
diseases are economically important in the affected continents especially in subsaharan 
Africa where it causes heavy losses in cattle. The causative agent of CBPP is Mycoplasma 
mycoides subsp. mycoides “SC” type.
To be pathogenic, mycoplasma cells need to adhere to the epithelial cells of the host. 
The terminal organelles or blebs unique to the flask-shaped mycoplasmas appear to mediate 
attachment to host epithelial cells. The mycoplasmal cytadherence proteins are concentrated 
at these sites (Kirchhoff et al. 1984; Baseman et al, 1982; Kahane et al, 1985; Krause et al, 
1983). Cytadhesin proteins involved in hemadsorption and virulence in M. pneumoniae 
have also been described (Krause et al, 1982). The PI protein (170 kDa) of M pneumoniae 
has been identified as a major adhesin. When M. pneumoniae cells were treated with 
trypsin, it resulted in the reversible loss of the PI protein. Bacterial cells that lost the PI 
protein were unable to adhere to epithelial cells and consequently were not pathogenic 
(Krause et al, 1983; Gorski et al, 1977; Hu et al, 1976; Hu et al, 1977). The PI protein was 
ultimately demonstrated to be localized at the terminal or tip organelle in M. pneumoniae
22
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(Feldner et al, 1982; Hu et al, 1982; Baseman et al, 1982). It was further demonstrated that 
only virulent mycoplasmas cluster the adhesin proteins at the tip organelle (Baseman et al, 
1982; Huet al, 1982).
A smaller protein involved in cytadherence was also identified in M. pneumoniae. The 
P30 (30 kDa) was similarly clustered at the tip organelle of pathogenic M. pneumoniae. It 
was further demonstrated that the P30 and PI proteins of M. pneumoniae have sequence 
homologies with each other (Baseman et al, 1987; Dallo et al, 1989; Dallo et al, 1990; 
Morrison-Plummer et al, 1986; Su et al, 1987; Inamine et al, 1989).
A protein similar to the PI protein of M. pneumoniae in cytadherence and similarly 
localized at the tip organelle was discovered in M. genitalium. The protein, PI40 (160 
kDa), has homologous sequences with the PI of M. pneumoniae (Morrison-Plummer et al, 
1987; Morrison-Plummer et al, 1987; Hu et al, 1987).
Southern blot hybridization with probes made from the genomic DNA of M. 
pneumoniae, M. genitalium and M. gallisepticum and probed against each other showed, 
apart from the usual rRNA hybridization bands, other hybridization bands suggestive of 
strong genomic homologies (Yogev et al, 1986). Subsequently probes made from the PI 
gene of M. Pneumoniae detected homologous sequences in M. genitalium and in M. 
gallisepticum at low stringency conditions suggesting the possible presence of a gene 
similar to the PI gene in these mycoplasmas. Since all three mycoplasmas are pathogenic 
and all have tropism for the lung tissue of their respective hosts, it was further suggested 
that a PI-like gene may be conserved in all pathogenic mycoplasmas (Dallo et al, 1990). 
Both the PI gene of M. Pneumoniae and the PI40 of M. genitalium were later cloned and
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their sequence determined. Their sequences showed areas of homology ranging from 62% 
to 100%. Both genes are over 4kb long (Su et al, 1987; Dallo et al, 1989).
A group of thirteen amino acids were later identified as the binding domain in the PI 
gene of M. pneumoniae. There are regions of the PI gene that exist as multiple copies but 
the 13-amino acid binding domain exists as a single copy in the gene (Su et al, 1987; Dallo 
etal, 1988; Dallo etal, 1991).
Since M. mycoides subsp. mycoides “SC” type is similarly pathogenic and has tropism 
for the lung tissue of cattle, as are the other mycoplasmas that possess cytadhesin genes, 
it was reasonable to assume that this cattle pathogen may also possess this conserved 
cytadhesin gene and that primers and probes made from homologous sequences of the PI 
gene of M. pneumoniae and the PI40 of M. genitalium may identify homologous regions 
from M. mycoides subsp. mycoides “SC” type.
Therefore this research was conducted to demonstrate the presence of the PI gene 
homologue of M. pneumoniae in M. mycoides subsp. mycoides “SC” type.
PCR primers were synthesized based on homologous regions between PI and PI40 
sequences and used to amplify DNA from M mycoides subsp. mycoides “SC” type strains. 
PCR products were obtained from these reactions and the DNA sequences were determined 
using PCR direct cycle sequencing and compared to that of the PI gene. In addition, DNA 
probes synthesized by PCR from regions of the “putative” PI gene of M. mycoides subsp. 
mycoides “SC” type were used in hybridization experiments to characterize the presence 
of this gene in several virulent strains and the T1 vaccine strain of M. mycoides subsp. 
mycoides “SC” type. Protein analysis of cell lysates of virulent and vaccine T1 strains were 
also performed.
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Materials and methods:
Cultures and DNA extraction:
Purified DNA extracted from five “SC” type strains of M. mycoides subsp. mycoides 
were received from Dr. D. Pitcher, British Public Health Laboratory, London, United 
Kingdom. The DNA were from four virulent strains (Oremit, PG1, Gladysdale, Poumerat) 
and one “vaccinal strain (KH3J)”. The PG1 is the type strain and was isolated in Africa, as 
was Oremit: the Gladysdale strain was isolated in Australia; Poumerat is a European strain. 
All are highly pathogenic. The KH3J was originally isolated in the Sudan as a virulent strain 
and later attenuated and used as a vaccine in some African countries. It was more virulent 
than the widely used T1 vaccine strain, which was isolated from an outbreak of CBPP in 
Tanzania. The use of KH3J was abandoned in the early 1970's as a vaccine in favor of the 
T1 because of the severe reactions it provoked in the animals at the site of inoculation.
More DNA from 4 M. mycoides subsp. mycoides “SC” type strains were extracted at 
the Kenya Agricultural Research Institute, Muguga, Kenya by the author. The DNA were 
from seven virulent strains (PG1, Oremit, Baringoni, Gladysdale, Iriri, Archer's Post, Mara) 
and two vaccinal strains (T1 and KH3J). Six of the seven virulent strains were isolated from 
outbreaks of CBPP in Africa.
Strains of M. pneumoniae were received from Dr. David Walker of the University of 
Texas Medical Branch at Galveston, Texas. The British, Kenyan and M. pneumoniae DNAs 
were kept in separate freezers.
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Culture media:
Culture media for M. mycoides subsp. mvcoides “SC” type strains from London. 
England:
The mycoplasma cells were grown on Friis agar in serial dilutions from 10'1 to 
10‘5 in an atmosphere of 95% N2, 5% C02 and incubated at 37°C. Single colonies were 
picked and subcultured into 2 ml of modified Hayflick’s broth and incubated at 37°C. When 
turbid, the 2 ml cultures were subcultured into 400 ml of the same media and incubated at 
37°C until late log phase when the indicator begins to change color (Pitcher, 1993). The 
modified Hayflick media consists of heart infusion broth (2.85 g); distilled water (90 ml); 
these are autoclaved at 121°C for 20 minutes. The following are then added aseptically: 
Horse serum (20 ml); calf thymus DNA (1.2 ml of 0.2% solution); fresh yeast extract (20 
ml of a 25% solution); thallium acetate (1 ml of a 1% solution); penicillin (0.25 ml of a 
20,000 IU/ml solution) and 0.0002% phenol red as the indicator. The pH was adjusted to 
7.8 (Pitcher, 1993).
Culture media for M. mvcoides subsp. mvcoides “SC” type virulent and T1 vaccine 
strains from Muguga. Kenva:
Newings tryptose broth modified by Gourley, 1964 was used to culture the 
bacteria. It consisted of 2% Bacto tryptose (Difco Laboratories, Detroit, Michigan); 0.50% 
Dextrose; 0.50% NaCl; 0.25% Na2HP04 (anhydrous); 0.50% Glycerol; 0.10% Yeast 
extract, pig serum and the volume brought to 100% with distilled water (Gourley, 1964). 
The bacterial cultures were incubated at 37°C until turbid (3-4 days) and then the DNA 
extraction procedure described below was followed.
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Culture media for M. pneumoniae:
The SP-4 media was prepared as described by Tully et al, 1979. The media 
consisted of 1.5 g of Mycoplasma broth base (Difco Laboratories, Detroit, Michigan), in 
67 ml deionized H20, 10 ml of 25% fresh yeast extract (Difco Laboratories, Detroit, 
Michigan), 20 ml unheated horse serum (Cell Culture Laboratory, LSU-Veterinary School), 
500 units of penicillin G, and thallium acetate (1:2000 final concentration), 0.5% glucose, 
0.002% phenol red. The pH was adjusted to 7.8 with 1 N NaOH (Tully et al, 1979).
DNA extraction of M. mvcoides subsp. mvcoides strains from London. UK and 
Muguga. Kenva:
The M. mycoides subsp. mycoides DNA was extracted following the procedure 
described by Taylor et al, 1992 and modified by Pitcher (1993). The mycoplasma cells were 
pelleted by centrifugation at 10,000 X g for 30 minutes at 4°C. The pellet was washed three 
times in PBS and resuspended in 5 ml TE. The cells were lysed by the addition of 100 pi 
of 25% SDS and 50 pi of 10 mg/m 1 proteinase K. and incubated at 37°C for two hours. R- 
nase A was added to 100 pg/ml and incubation continued at 37°C for another 30 minutes. 
The lysate was sequentially extracted with 5 ml volumes of phenol:chloroform:isoamyI 
alcohol (25:24:1); chloroform:isoamyl alcohol (24:1). The DNA was precipitated by the 
addition of 500 pi of 3 M sodium acetate and 10 ml of ice-cold absolute ethanol. After 
centrifugation, the pellet was washed three times in 70% ethanol without centrifugation
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allowing the pellet to stand at room temperature for 5 minutes between washes. The final 
DNA was resuspended in TE and stored at -20°C (Pitcher, 1993).
DNA extraction of M. pneumoniae:
The M. pneumoniae culture was centrifuged at 12,000 rpm for 20 minutes in 
a JA-17 rotor. The pellet was twice washed in TE buffer and finally resuspended in 1 ml 
TE buffer. The DNA was released from the mycoplasma cells by boiling in a 94°C 
waterbath for 5 minutes and freezing in -168°C liquid nitrogen for 5 minutes. The boiling- 
freezing process was repeated two more times. The lysate was centrifuged at 4000 rpm for 
eight minutes. The DNA precipitated with I ml 70% ethanol and stored at -70°C for 24 
hours. The ethanol was drained off carefully and the DNA resuspended in 200 tA TE. A 
small amount of the DNA was diluted 1:30 and spectrophotometric readings taken in UV 
at 230, 260, 280 nm to determine amount and purity of DNA. The rest of the DNA was 
diluted 1:10 and used in the PCR amplification.
Primers for PCR amplification:
To identify regions for primers to amplify fragments of the “putative” PI gene 
of M. mycoides subsp. mycoides “SC” type, the PI gene sequence of M. pneumoniae and 
the sequence of PI40 of M. genitalium were compared. Primer sets were selected from 
regions of 100% homology between the two strains. Several primer sets were developed 
from sequence analysis and after trials, two were chosen for investigation (Appendix A).
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The first primer set, MP-2 was chosen from DNA sequences in the 5' end of the 
PI gene of M. pneumoniae in the published sequence of the gene:
MP-2 forward primer(MP-2F) 1228-1245 bases: 5' CCC AAG TGA AAC CAC CA 3'. 
MP-2 reverse primer(MP-2R) 1698-1716 bases: 5' TGG TAC ATA TTC AAA CCA 3’. The 
primers amplify a fragment of 488 base pairs (Appendix A).
A second primer set named MP-3 was chosen from DNA sequences which 
flanked the sequence encoding the 13-amino acid binding domain of M. pneumoniae in the 
published sequence of PI.
The MP-3 forward primer (MP-3F) sequence is: 5' CTC GCG CCT AAT ACT 3'.
The MP-3 reverse primer (MP-3R) sequence is: 5' AGG GTT CAC ACT TGC 3'. The 
expected fragment size was 303 base pairs (Appendix A).
A third primer set, MP-V, was selected from the lower end of the sequence 
between bases 374-832 of the CAP-21 gene insert described by Taylor et al, 1992. It 
produces a fragment of 458 bp (Appendix B).
MP-V forward primer(MP-VF): 5' AGT TCG TCG TAT TGG AGG AGC T 3’
MP-V reverse primer(MP-VR): 5' TAA TCC CAC GTT CTT GCT CTT GAG CCA 3'.
PCR amplification parameters:
DNA from two virulent strains of M mycoides subsp. mycoides “SC” type 
(PG1, Oremit) and DNA from M. pneumoniae were used initially in the search for the 
possible presence of a cytadhesin gene in the former. Once DNA fragments from the 
“putative” PI gene of PG1 and Oremit were amplified and the DNA sequences was
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obtained, DNA from the vaccinal strain T1 and “KH3J” and all other virulent strains were 
analyzed in the same manner.
DNA template and primer concentrations:
DNA sample dilutions of 1:10,1:100, and primer concentration of 5,10 and 20 
pM were tested and the optimum dilution of DNA and primer concentration established. 
A 1:100 template DNA dilution and a primer concentration of 20 uM were chosen as the 
optimum dilution and concentration for the experimentation.
PCR reaction mixture:
A 100 mi reaction mixture consisting of 267.5 pi of sterile H20 , 25 pi of each 
primer, 80 pi of dNTP mix, 50 pi of 10X buffer, 2.5 pi of Taq polymerase for 5 PCR 
reaction tubes, with 2 pi of the 1:100 template DNA sample dilution was used. The reaction 
mixture amounts except for the template DNA were doubled for the 10 reaction mixture. 
The tubes were covered with 70 pi mineral oil.
The reaction mixture was dispensed in 500 pi yellow PCR tubes (PGC 
Scientifics, Gaithersburg, MD). Five or ten reaction tubes were set up: Tubes 1 and 2 
contained 2 pi of the 1:100 DNA dilution of strain PG1; tubes 3 and 4 contained 2 pi of the 
1:100 DNA dilution of strain Oremit; tubes 5 and 6 contained 2 pi of the 1:100 DNA 
dilution of M. pneumoniae used as the positive control; tubes 7 and 8 contained 2 pi of the 
1:100 DNA dilutions of strain KH3J; tubes 9 and 10 contained no DNA but received 2 pi 
of sterile H20  and used as the negative control.
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The room the reaction mixture was prepared was separated from the PCR room 
by two floors. The addition of the template DNA was performed in still another room.
Thermal cycling conditions:
PCR amplification of template DNA was carried out in a TCI thermal cycler 
(Perkin Elmer Corp., Stafford, TX) using the following conditions: an initial cycle for 5 
minutes at 94°C, followed by 45 cycles of 94°C for 2 minutes, 60°C for 30 seconds and 
72°C for 1 minute and an additional cycle of 10 minutes at 72°C. The optimum conditions 
established for the MP-2 and MP-3 primer sets in the amplification of their respective 
fragments are: 20 ^M primer concentration (120 pg and 80 pg respectively for PG1 and T1 
template DNA), and temperatures of 94°C denaturing, 60°C annealing and 72°C extending. 
For the MP-V primer set, the optimum amplifying conditions are: 10 fjM primer 
concentration (40 pg template DNA) and temperatures of 94°C denaturing, 58°C annealing 
and 72 °C extending.
Gel electrophoresis of PCR products:
A volume of 50 ml of two percent agarose (1% Nusieve and 1% Seakem) in IX 
TE (TRIS-EDTA pH 6.8) was used to make the gels for the detection of PCR products 
(amplicons). Preparative gels for purification of DNA fragments to be used as DNA probes 
were similarly prepared but with a volume of 75 ml. Twenty microliters (20 pi) of the PCR 
amplification products together with the controls was placed in fresh tubes and 3 pi of gel 
loading solution (Sigma, St.Louis, MO) added. This was pipeted into the gel wells and
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electrophoresed with a current of 80 volts for 1.5 hours. Eight and half (8.5 ul) microliters 
of a 123 bp DNA ladder was used as a molecular weight marker to measure molecular 
weights of the amplified fragments.
The gels were photographed on a FOTO/PREP I UV translluminator with a 
Polaroid camera and film (Fotodyne, INC., New Berlin, Wisconsin).
Purification of PCR product for direct DNA cvcle sequencing:
Two methods were used to purify the PCR products for DNA sequencing:
Method 1: The amplified products of each strain (50 fA) were added together and 
electrophoresed on a 3% Nusieve/Seakem preparative gel. The gel was run at 70 volts for 
2.5 hours. Under UV light, the fragment was cut from the gel with a sterile scalpel and 
placed in a dialysis bag containing 500 pi TE and the DNA was electroeluted by subjecting 
the gel slice bag to 100 volts for 20-30 minutes (Ausubel et al, 1992).
The electroeluted DNA was concentrated with Microcon concentrations. DNA was equally
divided between two concentrates and spun at 2000 rpm for 15 minutes. Both tubes were
then inverted into the second set of Microcon tubes and spun for another 5 minutes at 4000
rpm in a microcentrifuge. Contents of the tubes were combined and the volume brought to
100 pi. Twenty microliters of the purified DNA fragment was electrophoresed to ascertain
the purity of the fragment.
Method 2: Ten microliters of each PCR product was added to 3 ul of dye and loaded on a 
6% TBE (Polycramide MiniGel-Novex Corp, San Diego, CA). The gel was then stained 
with 0.02% ethidium bromide solution for 15 minutes. DNA was separated at 150 volts for
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50 minutes. The desired band was then cut from the gel with a sterile scalpel, placed in 15 
A  sterile H20  in a sterile PCR tube and crushed with a pipette tip. The DNA was allowed 
to elute from the gel for 24 hours. 2 A  of this preparation was used for sequencing.
DNA sequencing:
A finol DNA sequencing kit (Promega Corp., Madison, WI) and direct 
sequencing procedure developed in the laboratory of Dr. Diana Williams of the Gillis W. 
Long Hansen’s Disease Center, Laboratory Research Branch in the Molecular Biology 
Department at LSU School of Veterinary Medicine was used to obtain DNA sequences of 
several regions of the “putative” PI-like gene of M. mycoides subsp. mycoides “SC” type 
strains. Briefly, sequencing primers were labelled with gamma 32P as follows: one 
microliter of primer (10 //M); three microliters of 32P dATP; one microliter of 10X 
poly kinase buffer; one and half microliters of T4 kinase (5 units); three and half microliters 
of H:0. A total volume of ten microliters. The reagents were gently mixed and incubated 
at 37°C for 20 minutes. The primer was then heat inactivated at 90°C for 2 minutes and 
drop pelleted by brief centrifugation in an ultra microcentrifuge and stored at -20°C until 
used.
Three microliters of the template DNA (1:20 dilution); five microliters of 5X 
sequencing buffer; one microliter of Taq polymerase; two microliters of the gamma 32P 
labelled primer; eight microliters of H:0, a total volume of 19 A- The reagents were gently 
mixed by pipetting.
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A set of PCR tubes labelled GATC were placed in a row. Four microliters of 
each dd/dNTP and three microliters of the sequencing reaction template mixture were 
added to each of these tubes. The mixture was drop pelleted by brief centrifugation in an 
ultra microcentrifuge.
The thermal cycling parameters were set as follows: The Thermal Cycler 
(Model 9600 Geneamp PCR System, Perkin Elmer Cetus, Norwalk, Connecticut) was 
preheated to 94°C. The reaction mixture was placed in the PCR and incubated at 94°C for 
7 minutes. Then a thermocycle program of 94°C for 30 seconds, 60°C for 30 seconds and 
70°C for 90 seconds was started for a total of 30 cycles. The cycling program was linked 
to a soak program of 4°C. The tubes were then removed from the thermal cycler and three 
microliters of stop solution dye added to each tube.
The sequencing gel solution (Gel Mix 6) was purchased from commercial 
sources (Promega, Madison, WI) and the gel was cast according to manufacturer 
instructions. The gel was pre-equilibrated for 2 hours at 70 °C before loading the samples. 
Twenty four well combs were used and four microliters of the samples loaded into each 
well. DNA was separated using 2200 volts for 1 hour and 30 minutes. After the run was 
complete, the gel was placed on 3 mm membrane, baked at 80°C for 1 hour and exposed 
to an X-ray film (X-OMAT AR, 35x43 cm, Eastman Kodak, Rochester, NY) for 16 hours.
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Results:
The primer set MP-2 amplified the expected 488 base pair fragment in M. 
pneumoniae and in all the virulent strains of M. mycoides subsp. mycoides “SC” type and 
the KH3J “vaccine strain” (Figure. 1). However, the primer set did not amplify the expected 
fragment in the vaccine strain Tl. The KH3J vaccine strain is much more virulent than the 
T1 strain and is no longer used as a vaccine strain and since it looked like it retained the 
“putative” PI-like gene, we excluded it as a vaccine strain. DNA sequence analysis of all 
the amplified fragments of the virulent strains of M. mycoides subsp. mycoides “SC” type 
showed that their sequence was 100% homologous with that of the M. pneumoniae 488 
base pair fragment amplified by the same primer set. The fragment was amplified at the 
annealing temperatures of 55°C, 58°C and 60°C while the other temperature parameters 
remained constant as described above.
Primer set MP-3 amplified the expected 303 base pair fragment in M. 
pneumoniae and in all the virulent strains of M. mycoides subsp. mycoides “SC” type. This 
primer set did not amplify the expected 303 base pair fragment in the vaccine strain Tl 
(Figure 2 and 3). Sequencing of all the amplified fragments from virulent strains of M. 
mycoides subsp. mycoides “SC” type showed that their sequence was almost 100% 
homologous with a single base pair difference with the sequence of the 303 base pair 
fragment of M. pneumoniae amplified by the same primer set (Figure 4). The codon 
sequence of the 13-amino acid binding domain of M. pneumoniae within the 303 base pair 
fragment was present exactly in the same order in all the virulent strains of M. mycoides 
subsp. mycoides “SC” type as in M. pneumoniae (Figure 4).
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Figure 1. The Expected 488 bp Fragment Amplified by 
the Primer Set MP-2. Lane 1 = Marker; Lane 2 = 
Oremit; Lane3 = PG1; Lanes4 & 5  =T1; Lane6 = 
negative control.
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To confirm the sequence homologies between M. pneumoniae and the virulent 
strains of M. mycoides subsp. mycoides “SC” Type in the amplified fragments was not the 
result of cross contamination, we tested the DNAs of the latter that were brought from 
Kenya that had absolutely no contact with the DNAs from Britain or with M. pneumoniae 
DNA. The sequence homology observed in the Kenyan DNA samples was exactly the same 
as the one previously observed and described. To further investigate whether inhibitors of 
PCR reactions was to blame for the inability to generate the 303 bp and 488 bp fragments 
in the T1 strains, dilutions (1:10, 1:100, 1:1000, 1:2000 and 1:5000) of T1 DNA were 
analyzed in the PCR and similar results were obtained. In addition, several T1 isolates were 
amplified using the two primer sets and no strain gave the expected product (figure 3). 
There were no detectable sequence differences between the different geographic strains 
with respect to the 488 bp, and 303 bp fragments apart from the fact that The primers MP-2 
and MP-3 were able to amplify the expected fragments in all the virulent strains of the 
CBPP agent from all the geographic regions represented but did not amplify the fragments 
in the T1 strains from Kenya, Tanzania and Ethiopia.
The third primer set MP-V was selected from the gene insert CAP-21 described 
and sequenced by Taylor et al, 1992. This gene insert, to our knowledge, has nothing to do 
with cytadherence and virulence. The primer set was selected from an area where all the 
strains sequenced in that study had 100% homology with each other. This primer set was 
chosen to investigate whether the T1 DNA was being inhibited and that the inhibition was 
a reason for both the MP-2 and MP-3 primer sets not being able to amplify the expected 
fragments in the vaccine strain T1. It was also selected to ascertain the assumed fact that
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a primer from a highly conserved region in the virulent M. mycoides cluster will also 
identify the T1 strain. The MP-V primer set amplified the expected 458 base pair fragment 
of the CAP-21 gene insert in all the virulent strains of M. mycoides subsp. mycoides “SC” 
type (Figure 5). It also amplified the expected fragment of 458 base pairs in the vaccine 
strain T1. The primer set did not amplify the 458 base pair fragment in M. pneumoniae and 
in M. genitalium (Figure 5)..
A probe made from the 458 base pair CAP-21 fragment hybridized with the 
virulent as well as the vaccine strain T1 but did not hybridize with genomic DNA from M. 
pneumoniae and M. genitalium. Sequencing a portion of the 458 base pair fragment 
amplified from T1 vaccine and virulent PG1 strains showed that the fragments were 100% 
homologous at least in the first 160 bp that were sequenced. This sequence was similar to 
the F38, Cal. Kid, Gladysdale, etc. strains of the M. mycoides cluster.
To investigate the possibility that the whole cytadherence gene may be missing 
from the T1 strain, a comparison was made between the protein pattern of the virulent 
strain PG1 and that of the vaccine strain T1. A 4-15% SDS-PAGE gradient gel and a 6% 
SDS-PAGE were used (BIO-RAD) to electrophorese the proteins. Mycoplasma mycoides 
subsp. mycoides “SC” type were grown as described above and centrifuged at 15,000 rpm 
for 30 minutes in a JA-17 rotor. I ml of 70% ethanol was added to the pelleted cells and 
kept at -20 °C until used. The ethanol was drained and the cells were resuspended in 1 ml 
sterile water and the protein content determined by the Lowry method (Lowry et al, 1953).
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1 2 3 4 5 6 7 8 9  10
Figure 2. The Expected 303 bp Fragment Amplified by the Primer 
Set MP-3. Lanes 1 & 10 = Marker; Lane 2 = Strain Oremit; Lane 
3 = PG1; Lane4=Tl; Lane 5 =T1; Lane 6 & 7 = M. pneumoniae; 
Lanes 8 & 9 = negative controls.
1 2 3 4  5 6
Figure 3. The Expected 303 bp Fragment Amplified by 
the Primer Set MP-3. Lane 1 = Marker; Lane 2 = PG1; 
Lane 3 = Tl-Kenya; Lane 4  = Tl-Kenya; Lane 5 = Tl- 
Tanzania; Lane 6 = negative control.
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PG1 GCA ACG CCG CAA AGA TGA A£ G  ACG ATG TTG AT**GOT ATT GTA 
MP GCA ACG CCG CAA AGA TGA ATG ACG ATG TTG AT**GGT ATT GTA 
CGC ACC CCA CTC GCT GAA CTG TTA GAT GGG** GAA GG ACA AC AGC CGC 
ACC CCA CTC GCT GAA CTG TTA GAT GGG** GAA GG ACA AC AGC
PG1TGA CACT GGT CCA CA AAG CGT GAA GTT C AA GTC TCC 
MP TGA CACT GGT CCA CA AAG CGT GAA GTT C AA GTC TCC
Figure 4. Comparison of the sequence of the PG1 strain of M. mycoides subsp. 
mycoides “SC” type and that of M. pneumoniae (MP) in the amplified 303 bp 
fragment.
Note: The two bases in which PG1 differs from MP are in bold and underlined. The 13- 
amino acid binding domain sequence is bracketed by the astericks and underlined.
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Figure S.' The Expected 458 bp Fragment Amplified by 
the Primer Set MP-V. Lane 1 = Marker; Lane 2 = M. 
pneumoniae; Lane 3 = M. genitalium; Lane 4 = PG1; 
Lane 5 = Oremit; Lane 6 = T 1; Lane 7 = negative 
control.
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The suspension was diluted to give a final concentration of I mg protein per ml. 
An equal volume of a 3% SDS was added, mixed, incubated at 37°C for 90 minutes and 
then centrifuged at 15,000 rpm for 30 minutes at 4°C in a JA-17 rotor. Protein 
concentration was again determined by the Lowry method. Alternatively, the SDS 
solubilization step was omitted. The ethanol was drained out and the pellets resuspended 
in sterile H20 . The protein content was determined by the Lowry method and dilutions of 
1:10, and 1:100 directly loaded into the gel. Twenty five microliters of 1 parts sample and 
2 parts sample buffer (Appendix C) were inoculated into each well and the gel placed in a 
Mini Protean II Cell (BIO-RAD) and electrophoresed for 5-6 hours at 50 volts for the 4- 
20% SDS gels and for 1 hour and 30 minutes at 150 volts for the 6% gels. After very 
promising results were seen in these precast gels, we decided to make longer gels with 
longer running time and also add a stacking gel to the separation gel (Appendix C). This 
gel was run at 150 volts for 7-8 hours. All gels were then immersed in a staining solution 
(Appendix C) for 30 minutes (Bio-Rad recommendation). The gels were then removed from 
the staining solution, immersed in destaining solution (Appendix C) and placed on an 
orbital shaker until a clear background became visible. A picture of the gel was then taken 
with a regular 35 mm camera and the pictures developed.
SDS PAGE analysis of cell lysates of virulent and T1 strains are shown in 
figures 6 and 7. The protein gel patterns were too complex to distinguish whether the 
cytadhesin gene was absent or altered in the T1 strains.
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Figure 6. Protein Pattern of the Virulent PG1 and the Vaccine T1 Strains of M. 
mycoides Subspecies mycoides “SC” Type using 12% Separating Gel with a 4% 
Stacking Gel: Lanes A, B, C, G, I = T1 Strain; Lanes D, E, F, H, J = PG1 Strain; 
Lane K = High Molecular Weight Marker; Lane L = Low Molecular Weight Marker.
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Figure 7. Protein Pattern of the Virulent PG1 and the Vaccine T1 Strains of M 
mycoides Subspecies mycoides “SC” Type using 7.5% Separating Gel with a 4% 
Stacking Gel: Lanes A, C, E. G, = T1 Strain; Lanes B, D, F, H = PG1 Strain; Lane 
1= High Molecular Weight Marker; Lane J = Low Molecular Weight Marker.
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The protein comparison showed that there are a number of proteins where the 
two strains differ, high, medium and low molecular weight proteins but since we did not 
know the molecular weight of the protein produced by the “putative” PI-like gene in this 
organism, we could not point to any definitive protein as the cytadhesin protein produced 
by the PI-like gene (Figures 6 & 7).
We established the maximum sensitivity of the primers at the following values:
1:106 dilution equivalent to 120 pg of PG1 and 80 pg of T1 template DNA. The specificity 
was established by including M. Pneumoniae and M. genitalium 1:100 diluted template 
DNA since the MP-V primer set is expected to amplify the 458 bp fragment in all the M. 
mycoides strains but not in the former strains. The primer set MP-V did just that.
To establish the maximum specificity of the PCR assay, we useM. pneumoniae, 
a human pathogen and M. genitalium another human pathogen. This was dictated by the 
lack of availability of other cattle mycoplasmas for differentiation. The two human 
pathogens were differentiated from the M. mycoides used in the study. Since M. mycoides 
cross reacts with the other cattle mycoplasmas serologically and is probably 
indistinguishible in cultures, it is necessary to have the isolates identified by other means 
such chemical testing and use of monoclonal antibodies and determine specifically their 
identify. With that knowledge, one can determine with certainty the specificy of the 
polymerase chain reaction assay since it is known what samples are exactly being tested.
It will also be necessary to test vaccinated animals and animals that have never 
been exposed to the agents and determine respectively the specificity of the assay regarding 
the T1 vaccine strain in the vaccinated animals and specificity of those uninfected. Besides 
it can very useful to use samples from known infected animals so that the epidemiological 
and microbiological sensitivity and specificity can be determined.
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Discussion:
The cytadherence and cytotoxicity of M mycoides subsp. mycoides “SC” type 
to both endothelial and epithelial cells has been described (Valdiviesco-Garcia et al, 1989). 
However, genes or proteins involved in their pathogenicity and virulence have not been 
previously described. Data presented in this study suggests that a cytadherence gene similar 
to the PI gene in M. pneumoniae and the PI40 inM  genitalium is present in M. mycoides 
subsp. mycoides “SC” type. The high degree of nucleic acid homology between M. 
mycoides subsp. mycoides “SC” type and PI suggest a conserved cytadherence gene in 
those pathogenic mycoplasmas that have tropism for the lung tissues. In addition, there 
appears to be an absolute conservation of the 13-amino acid binding domain of this gene 
product giving further evidence that the mechanism of epithelial cell adherence is similar 
between these mycoplasma species. The observation that both PI gene primer sets did not 
amplify the expected fragments in the vaccinal strain T1 is suggestive that the gene is 
missing or has a major deletion or insertion of genetic material in this strain. We 
demonstrated that the lack of amplification in the T1 DNA was not due to inhibition of 
PCR reactions and that all T1 strains showed the same profile.
The inability to amplify the expected fragments in the T1 strain may have one 
or more of the following possible explanations:
(1). Virulence genes are carried within the chromosomal DNA of the organism or 
extrachromosomally by plasmids. Assuming that the cytadherence gene in M. mycoides 
subsp. mycoides “SC” type is associated with a plasmid, then it is possible that the plasmid 
may have been lost (ejected) during the attenuation process of the vaccine strain T1 and this
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The inability to amplify the expected fragments in the T1 strain may have one 
or more of the following possible explanations:
(1). Virulence genes are carried within the chromosomal DNA of the organism or 
extrachromosomally by plasmids. Assuming that the cytadherence gene in M. mycoides 
subsp. mycoides “SC” type is associated with a plasmid, then it is possible that the plasmid 
may have been lost (ejected) during the attenuation process of the vaccine strain T1 and this 
may account for the inability of the primers MP-2 and MP-3 to amplify their respective 
fragments in this strain. If this is the case, it is reasonable to assume that the plasmid is 
present in all the virulent strains and prolonged storage has no effect on the plasmid where 
in some other organisms it is ejected in prolonged storage. So far only two plasmids have 
been identified in M. mycoides subsp. mycoides and none has been associated with 
virulence (Dybvig et al, 1990).
(2). It is possible that mutations occurred in the cytadherence gene during attenuation and 
that the gene product may have not been produced or a different product unable to perform 
the function of cytadherence may have been produced.
(3). The entire cytadherence gene may have been deleted during the attenuation process. 
Either scenario (2 or 3) may explain the molecular basis for the difference in virulence and 
pathogenicity between the virulent wild strains and the vaccinal T1 strain. The KH3J 
behaved much the same as the virulent strains producing the expected fragments from both 
MP-2 and MP-3. It is known that this strain has been observed to be much more pathogenic 
than the T1 and slightly less than the wild strains. Because of this virulence, its use was 
abandoned in favor of the T1 strain used only in Africa. This study may have given the
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molecular basis for its sustained virulence suggesting that it may not have lost the 
cytadherence gene at all.
(4). A major insertion mat have been added to the “putative” PI-like gene in the T1 strain 
and this may have affected the gene product.
Because the PI gene did not appear to be intact in the T1 strain, we attempted 
to determine if the “putative” PI-like product was produced in this strain by comparing the 
protein profiles of the virulent PG1 and the vaccine T1 strains (Figures 6 & 7).
The fact that one of the primers (MP-V) clearly differentiated M. mycoides 
subsp. mycoides “SC” type from M. pneumoniae and M. genitalium (closely related with 
respect to the cytadherence gene and taxonomically) may be very useful in the diagnosis 
of this organism from the other mycoplasmas that affect the same host and that otherwise 
pose difficulty in differentiation on the basis of serological tests because of cross reactions 
or on the basis of microbiological tests because of the inability of most laboratories in 
developing as well as in developed countries to perform specialized tests for identification, 
partly due to the lack of interest in this economically important pathogen. The inability of 
the MP-V primer set to amplify the 458 bp fragment in M. pneumoniae and M. genitalium 
suggested that the primer set MP-V recognizes only the M. mycoides cluster and does not 
recognize its close relatives M. pneumoniae and M. genitalium. On the other hand, the 
amplification of the 458 bp fragment in the T1 strain indicated that the T1 DNA was 
amplifiable and no inhibiting factors were responsible for the failure of the MP-2 and MP-3 
to amplify their respective fragments in this strain.
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Because, the MP-2 and MP-3 primers are able to differentiate the virulent 
strains of the organism from the vaccine strain T1 may finally put to rest whether infection 
is due or not to the T1 strain in immunosuppressed animals that have been vaccinated with 
this strain and subsequently became infected. This ability of the two primers may be 
employed as a rapid method of differentiation in cases where viable organisms of M. 
mycoides subsp. mycoides are isolated from Somali cattle exports and elsewhere. If vaccine 
strain DNA is detected it will be further proof that the animals had been vaccinated and that 
any CBPP-like symptoms seen in these animals should be ascribed to diseases other than 
CBPP. In addition, all primer sets MP-2, MP-3 and MP-V may become very useful in 
determining whether ticks and fleas transmit the organism from infected animals to 
susceptible ones through their ability to identify whether the isolated organisms possess or 
lack the cytadhesin gene. Furthermore, the primer set MP-V may be employed in 
determining if any member of the M. mycoides cluster and particularly the “SC” type 
affects the wildlife population of east Africa, an important issue in the control of CBPP. All 
three primer sets may be used to study outbreaks of CBPP where organisms isolated at the 
beginning of an outbreak are more pathogenic than those isolated at the end of it. 
Specifically with MP-2 and MP-3, it can be studied whether the organisms isolated at the 
end of the outbreak can be classified as virulent forms or as attenuated forms and show 
similar pattern with the vaccine strain Tl.
Both primers MP-2 and MP-3 may be extremely useful in anticipating 
outbreaks of the disease by detecting possibly chronic carriers and animals incubating the 
organism, important circumstances essential in initiating outbreaks. While these primers
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may provide an early detection method for the disease agent, effective outbreak 
management, surveillance and proactive vaccination are some of the ingredients needed for 
the efficient control and eventual eradication of CBPP.
The full characterization of the entire gene should be done in a future study. The 
information gained may be useful to define the mechanism of attenuation and to 
manufacture specific primers to differentiate this important cattle pathogen not only from 
the T1 strain but also from the other members of the M. mycoides cluster. The whole gene 
can again be used to probe for homologous sequences in a search for other genes involved 
in cytadherence. The rationale for this later undertaking is based on the fact that in both M. 
pneumoniae and M. genitalium, smaller cytadherence genes were identified that have 
homologous sequences respectively with the PI and PI40 genes.
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Chapter 3. Development of a Multiplex PCR Assay for Detection of M. mycoides 
subsp. mycoides “SC” Type DNA from Purified DNA Samples and from Crude
Field Specimen
Introduction:
Contagious bovine pleuropneumonia (CBPP) is a socioeconomically important 
disease in Somalia where it is endemic. Since the economy of the country is totally 
dependent on the livestock sector, the control and eradication of CBPP is socially and 
economically desirable particularly in animals destined for export from which more than 
80% of the country’s foreign currency earnings come from. Obstacles to reaching the 
above objective are many. Among them:
a. Funding of the programs. The reliance of donor funding for such socioeconomically 
important programs has been a total disaster because governments do not allocate funding 
for the continuance of the program after the donor funding has run out with the inevitable 
recurrence of a disease that was once under control.
b. Many important aspects of the disease essential for a successful control are not known 
or have received scant research attention. One such aspect is whether the vaccine strain T1 
used extensively in vaccination campaigns reacquires its virulence in conditions where an 
animal is subjected to stressing conditions such as transportation, or other infections and 
infestations. This aspect is very important in that Mycoplasma mycoides subsp. mycoides 
“SC” Type has been isolated from exported animals previously vaccinated with T1 that 
have come down with CBPP-like symptoms en route to or on arrival at their destination. 
One of the difficulties in investigating these incidents has been the problem of identifying 
the isolated organism as a virulent strain or as a T1 vaccine strain.
51
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
52
Since traditional methods of detection and identification of M. mycoides subsp. 
mycoides “SC” type such as serology can not differentiate the virulent strains from the 
vaccine strain T1 through the antibody response they provoke, nor are the other 
microbiological methods able to differentiate the strains from each other, it became 
necessary to investigate whether a genetically-based method of identification and 
differentiation could potentially detect differences among these strains. Data obtained in 
the first part of this research suggested that this was possible using sequences of the 
“putative” PI-like gene and CAP-21 gene insert.
Since the T1 strain can usually be isolated from an animal that comes down 
with a debilitating infection within three months of being vaccinated with the strain, the 
export animals that come down with a disease are expected to have viable T1 strain in their 
respiratory canal and particularly in lung exudate if the disease brings about an 
inflammation of the lungs. Besides, in any outbreak of CBPP the etiologic agent is found 
in abundance in the lung exudate produced by the inflammation of the lungs and the pleura. 
Therefore lung exudate from animals suspected of having CBPP were used in this analysis. 
We also tested with the PCR assay the lung homogenate and nasal swabs from the same 
animals.
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Materials and methods:
With three primer sets, one of which amplifies a 458 bp fragment in virulent 
strains as well as in the T1 strain of M. mycoides subsp. mycoides “SC” Type and the others 
amplifying their respective fragments only in the virulent strains of the organism, it was 
decided to develop a multiplex PCR assay using the MP-3 primer set that amplifies a 303 
bp fragment in the virulent strains and the MP-V primer which amplifies the 458 bp 
fragment in the vaccine strain T1 as well as the virulent strains. The multiplex PCR assay 
was expected to amplify two fragments from all the virulent strains (303 bp and 458 bp) 
and one fragment in the vaccine strain T1 (458 bp) thus obtaining an assay that can 
differentiate the two strains in one amplification process. We determined the optimum 
amplification parameters: each reaction tube receiving 10 A  of the forward and 10 A  of the 
reverse of a 20 ^M MP-3 primer concentration and 2-3 A  of the forward and 2-3 tA of the 
reverse of a 3-5 mM MP-V primer concentration. The temperature conditions established 
were: 94°C denaturing, 58°C annealing and 72°C extending. We then used this assay to test 
crudely prepared samples from Kenya.
Sensitivity and specificity determination of the PCR assay using the known strain 
DNA’s (virulent strains and vaccine strain Tl):
The purified DNA samples were used in the following forms: 1:10 
(PGl=120Mg; Tl=80/zg), 1:100 (PGl=12Mg; Tl=8^g), 1:1000 (PGl=1200ng; Tl=800ng), 
1:10,000 (PGl=120ng; Tl=80ng), 1:100,000 (PGl=l2ng; Tl=8ng) and 1:1,000,000 
(PG1=120 pg; Tl=80 pg) dilutions of PG1 and Tl. A 10 reaction tube mixture was
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prepared as follows: 535 A  sterile H ,0, 160 (A dNTP mix (125 1^ of each dNTP added to 
500 fA sterile H20), 5 /A Taq polymerase and 100 /A of 10X buffer containing MgCU were 
added together, mixed and 90 A  dispensed into each of 10 PCR reaction tubes. 10 A  of the 
forward and 10 A  of the reverse of primer set MP-3 at a concentration of 20 a*M were first 
added to each tube, then 2 A  of the forward and 2 A  of the reverse primer set MP-V at a 
concentration of 3 //M added into each reaction tube. 70 A  of mineral oil was overlaid in 
each tube and the PCR run at 94°C denaturing, 58°C annealing and 72°C extending for 45 
cycles with an additional 10 minute extension at the end of the cycles. The ninth reaction 
tube contained M. pneumoniae or M. genitalium DNA while the tenth tube contained no 
DNA. Both reaction tubes were included as controls. The PCR product was then processed 
as described before.
Samples:
Cultures: Known laboratory strains of both the virulent and the vaccine Tl 
strains were grown and DNA extracted as described in section 2. DNA samples of the 
virulent strains Oremit and PG1 and of the vaccine strain Tl were used to test the 
sensitivity and specificity of the PCR assay.
Tissue Samples: A total of 62 field samples that were collected from field 
outbreaks of CBPP-like disease syndrome were chosen. Some of the samples were 
generously provided by the Muguga laboratory and were from outbreaks between 1980 and 
1990. The rest of the samples were collected from suspected outbreaks in 1994. The 
samples were from diseased animals whose recent history included vaccination against
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CBPP with the Tl strain. Each sample and their respective serums were tested serologically 
and culturally when available. The samples consisted of lung tissue, lung exudate and nasal 
swabs and were processed as follows:
(1). Lung tissue: 5 grams of lung tissue were minced and homogenized in 5-10 ml sterile 
water. Another 5-10 ml sterile water was added to the homogenate if it looked dry. The 
homogenate was then centrifuged at 3000 rpm for 10 minutes and the supernatant collected 
in a fresh sterile 2 mi centrifuge tube and centrifuged at 15,000 rpm for 20-30 minutes in 
a JA-17 rotor. The supernatant was drained off and 1 ml of 70% ethanol added to the pellet 
and kept at -20°C. When ready to be used, the samples were centrifuged at 10,000 rpm for 
10 minutes in a microcentrifuge and the ethanol drained out. The pellet was then 
resuspended in 200 ^1TE and freeze-boiled 3 times for 5 minutes each. 10 1^ of the lysate 
was then used in the PCR assay.
(2). Nasal swabs: The end of the swab was broken off and immersed in 1 ml of 10% 
sputalyzine and let sit for 15 minutes at room temperature and vortex mixed for 30 seconds. 
The swab was removed and the sample left to stand for 5 minutes. The sample was then 
centrifuged for 10 minutes at 10,000 rpm in a microcentrifuge and resuspended in 200 iA 
sterile water. 100 (A of the suspension was dropped into a 2 ml microcentrifuge tube and 
1 ml of 70% ethanol added. The other 100 /A was freeze-boiled 3 times for 5 minutes each 
and both samples kept at -20 °C until used. Before storage, both sample types were cultured 
for viability. None was found. Before use, the ethanol-fixed portion was freeze-boiled 3 
times for 5 minutes each in the presence of TE.
(3). Lung exudate: 5-10 ml of the lung exudate was centrifuged at 15,000 rpm for 20-30 
minutes in a JA-17 centrifuge. The supernatant was drained and 1 ml of 70% ethanol added
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to the pellet and stored at -20 8C. Before use, the samples were centrifuged at 10,000 rpm 
for 10 minutes in a microcentrifuge and the ethanol drained off. The pellets were then 
resuspended in 200 (A TE and freeze-boiled 3 times for 5 minutes each. 10 [A of the lysate 
were used in the PCR assay.
The 62 lung exudate samples were run with the assay 20 samples at a time, 18 
of the field samples. The 19th tube contained M. pneumoniae or M. genitalium DNA as a 
known control and the 20th tube contained no DNA at all and was used as a negative 
control. The remaining 8 samples were run in the 4th PCR assay with the two controls. In 
all four runs of the assay, the same thermal cycler was used at the same conditions 
described above. Dilutions of neat, 1:10 and 1:100 of each sample was tested and results 
recorded as positive or negative regardless of the dilution factor.
Field samples (lung exudate) were collected from previously vaccinated animals 
in a suspected CBPP-like disease outbreak. However, we selected only those that had serum 
for serologic testing and one or more of the other specimen for culturing. These results 
were recorded. Two serological tests were performed: The rapid slide agglutination test 
described by Lindley, 1958 (Lindley, 1958) and the ELISA test described by Kalif, 1992 
(Kalif, 1992). The culture was done on solid DE media as described by Provost et al, 1987 
(Provost et al, 1992). The lung homogenate and nasal swabs were also tested with the 
assay.
Optimum PCR cycling parameters: 94°C danaturing, 58°C annealing and 72°C 
extension for 45 cycles. At the end of the cycles, a further 10 minute extension was added.
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PCR amplification of the field samples:
Characterization of the multiplex PCR assay for differentiation of virulent and 
vaccine strains of M. mycoides subsp. mycoides “SC” type in field specimen was 
accomplished using the following protocol: 10 A  of the crude specimen preparations were 
added to each reaction tube and the template DNA was amplified using the optimal 
conditions for the multiplex PCR described above. In this assay, 20 reaction tubes were set 
up, eighteen of them containing samples, and the other two used as positive and negative 
controls. Twenty reactions were prepared as a stock: 1070 A  sterile H20 , 320 A  dNTP mix. 
10 (A Amplitaq and 200 (A of the 10X buffer. The reagents were mixed and 90 A- dispensed 
into each reaction tube. Then 10 A  of the forward and 10 A  of the reverse of the primer set 
MP-3 at 20 concentration was added into each reaction tube as well as 2 A  of the 
forward and 2 A  of the reverse of the primer set MP-V at 3 a*M concentration. Again the 
reagents were mixed and 70 A  of mineral oil overlaid in each reaction tube. 10 1^ of the 
sample was then dropped at the bottom of the tube and mixed. All 20 reaction tubes were 
put in the thermal cycler and run as described using the optimum cycling parameters 
described above. After the PCR cycles were completed, 18 A  of the PCR product was 
mixed with 3 A  of a gel loading solution and loaded on to a 2% agarose gel (1% Seakem 
and 1% Nusieve) in the presence of 0.01% ethidium bromide and electrophoresed at 80 
volts for I hour and 30 minutes in TAE buffer. A photograph of the gel was taken using 
UV translluminator and a Polaroid camera.
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Results: 
Sensitivity and specificity of the PCR assay:
To measure the sensitivity of the primers, we determined the least amount of 
template DNA that the primers can amplify their respective fragments from known virulent 
M. mycoides subsp. mycoides “SC” Type DNA and from the vaccinal Tl strain. The 
sensitivity of the primers was established at the following values: PG1=120 pg and Tl=80 
pg. To measure their specificity, we included in the testing DNA samples at dilutions of 
1:100 from M. pneumoniae and M. genitalium, both human pathogens. We had no other 
cattle Mycoplasmas to test the specificity of the PCR assay.
The multiplex PCR assay successfully differentiated the virulent strains of M. 
Mycoides subsp. mycoides “SC” Type from the vaccine Tl strain by amplifying 2 
fragments, the 303 bp and the 458 bp in the virulent strains and only one fragment, the 458 
bp in the vaccine Tl strain (Figure 8). The assay also amplified the 303 bp fragment in M. 
pneumoniae and M. genitalium but did not amplify the 458 bp fragment in both organisms 
(Figure 9).
A comparison of a 160 bp sequence between the virulent PG1 strain and the 
vaccine Tl strain in the 458 bp fragment produced by the MP-V primer set revealed that 
they were similar and when compared to other sequenced strains, it showed that it was 
similar with the sequences of Gladysdale and F38 and M  capricolum strains published by 
Taylor et al 1992.
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Figure 8. Multiplex PCR with Primers MP-3 and MP- 
V. Lane 1 = Marker; Lanes 2 ,3 , & 4 = PG1; Lanes 5, 
6, & 7 = T1; Lane 8 = negative control.
1 2 3 4 5 6 7 8 9  10 11
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Figure 9. Multiplex PCR with Primers MP-3 and MP- 
V. Lanes 1 & 11 = Marker; Lanes 2 = M. pneumoniae; 
Lane 3,4, & 5 = PGl; Lane 6 = M. genitalium; Lanes 
7,8, & 9 = Oremit; Lane 10 = T l.
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Multiplex PCR assay of the field samples:
Of the 62 samples , 59 were serologically positive for M. mycoides subsp. 
mycoides “SC” Type antibodies. The remaining 3 samples were negative and were included 
as known negative samples. 11 samples that were seropositive were also culture positive 
for the vaccine Tl strain. The multiplex PCR assay detected 19 positive samples giving the 
single fragment profile of the Tl strain DNA (Figure 10 and Table 1).
The PCR assay produced the 458 bp fragment in all 19 samples at dilutions of 
neat, 1:10, 1:100. Of these 19 specimen, 11 were culture positive for M. mycoides subsp. 
mycoides “SC” type. Pure cultures from the 11 culture positive samples were previously 
inoculated by intubation into susceptible cattle in Kenya and were found not to cause 
clinical CBPP although antibodies against the organism were detected after 4 weeks 
(Personal communication from Dr. Mugera of the Muguga Laboratory).
Of the nineteen (19) samples that were positive for Tl vaccine strain in the 
multiplex Polymerase chain reaction (PCR) assay, all were from different herds and none 
has any connection with the others. Five of those positive samples are shown in figure 10. 
The rest have not been displayed because of the similarities of the pattern of their 
manifestation.
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Figure 10. 5 of the 19 field specimens detected by the 
multiplex PCR assay as T1 strains.
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Table 1. Comparison of culture, serology and PCR of the lung exudate samples from 
cattle of CBPP-suspect herds in Kenya
Positive Negative Total
Serology 59 3 62
Culture 11 51 62
PCR 19 43 62
Table 2. Comparison of serology and culture of field samples
Serology
Positive Negative Total
Culture Positive 11 0 11
Negative 48 3 51
Total 59 3 62
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PCR Positive 11 8 19
Negative 0 43 43
Total 11 51 62
Table 4. Comparison of serology and PCR of the field samples
Serology
Positive Negative Total
Positive 19 0 19
Negative 40 3 43
Total 59 3 62
Note: The serological tests used to test the serum samples were the rapid slide agglutination 
test and ELISA. Only animals whose serums showed positive on both tests were included 
in the samples that were tested with the PCR assay. The culturing of the samples was done 
on solid DE media and the samples cultured were those of the lung exudate. Only animals 
whose serum samples as well as their lung exudate samples were available were included 
in the PCR assay test. The Multiplex PCR assay was also performed on the lung 
homogenate and nasal swabs with similar results.
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Discussion:
Both the culture and serological test did not, however, go beyond classifying 
the sample results as possible M. mycoides subsp, mycoides “SC” Type positive since both 
non-specific reactions due to a possible presence of an IgG-FC receptor on the organism 
and cross-reactions due to other bovine mycoplasmal infections can be responsible and 
since on the basis of culture characteristics, it is difficult to differentiate the various bovine 
mycoplasmas from each other and between the M. mycoides cluster.
Having no idea of how much M. mycoides subsp. mycoides “SC” Type DNA 
there was in each sample if any, we relied on the fact that if there was any sample that 
became positive in the PCR assay, we run that sample as neat, 1:10 and 1:100, 1:1000,
i
1:10000, 1:100,000 and 1:1,000,000 dilutions to judge the amount of DNA present in the 
sample. The inclusion of the primer set MP-V in the multiplex PCR assay also set the 
specificity of the assay by not amplifying the 458 bp fragment in M. pneumoniae and M 
genitalium. The non-amplification of the 458 bp fragment in M. pneumoniae and M. 
genitalium established the specificity of the assay.
Due to the inaccuracies of serological tests caused by both non-specific 
reactions and cross-reactions and their lack of sensitivity to carrier animals and animals 
incubating the organism, the multiplex PCR assay may be used as a tool to identify virulent 
M. mycoides subsp. mycoides “SC” type in herds. The difficulty in isolating M. mycoides 
from field samples through culturing especially in chronic carriers and animals incubating 
the disease may also make the PCR assay very valuable in predicting possible outbreaks 
and thus making possible the institution of contingency plans for prevention and outbreak
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
65
containment. Furthermore, the assay may also be useful in detecting the organism from 
decomposing animals so that a correct diagnosis of the cause of death can be determined.
Since we reasonably expected more samples to be positive for the T1 strain, the 
detection of only 19 of the 59 samples that were serologically positive may mean that most 
of the animals were vaccinated long before (more than 3 months) the sampling day and that 
all viable T1 strain organisms were cleared from the body. No records were available to 
substantiate this hypothesis.
In specimens which were culture and PCR negative yet serologically positive, 
both the rapid slide agglutination and the ELISA tests may have been detecting cross­
reactive antibodies produced as a result of an infection with other mycoplasma-induced 
diseases. It is also possible that reaction was due to a non-specific reaction which is 
common in Mycoplasma serology tests (Kalif, 1992) or detecting waning antibodies from 
a past infection or vaccination or that it may have been due to a non-specific reaction and 
that the investigators knowing beforehand that the samples were from an outbreak of 
CBPP-like disease may have classified it hastily as positive at the sight of a reaction 
without further verification by measuring the amount of antibody they were “detecting”. 
The consequences of hasty judgement can have important economic implications especially 
in Somalia where if such an animal turns up in an export shipment, the whole shipment is 
abandoned and the herd from which that animal came from (if known) will never get 
another chance to sell their animals for the export market.
Given the fact that the samples were from animals in the middle of a suspected 
CBPP outbreak when the etiologic agent can be found in abundance in the lung tissue, lung 
exudate and is shed in large amounts with the nasal droplets, only a combined 30 samples
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were positive in culture and in the PCR assay is suggestive of a misdiagnosed outbreak. 
Besides, if this was a real CBPP outbreak, it is surprising at this early stage of an outbreak 
to detect antibodies. It is the opinion of this investigator that the serological test was 
actually detecting the antibodies produced against the previous vaccination or a past natural 
infection.
All culture positive specimens were PCR positive for M. mycoides subsp. 
mycoides “SC” type. In addition, 8 culture negative were PCR positive. Since the 
sensitivity of this assay was found to be a detection of less than 1000 organisms, it is 
possible that the assay can detect that number of organisms in the presence of heavy 
contamination and decomposition where it may be impossible to isolate M. mycoides subsp. 
mycoides “SC” Type culturally and these few organisms are not enough in number to 
provoke a detectable antibody titer.
Some plausible explanations for the 19 samples detected by the PCR assay 
being T1 vaccine strains are:
a. The stress brought on by the journey may have given a few viable T1 organisms from 
the previous vaccination a chance to multiply again.
b. The suspected CBPP-like disease may have in fact been another infectious disease and 
that it may have weakened the animal that still harbored viable Tl organisms and thus have 
given the organism a chance to multiply.
C. The animal may have been immunosuppressed by such diseases as trypanosomiasis, 
dermatophytosis, etc. and that the vaccine strain from the vaccination may have remained 
active multiplying in the animal.
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Since no virulent strain DNA was detected, it is probable that the initial CBPP 
diagnosis was a mistaken one and that the outbreaks may actually have been due to such 
diseases as pasteurellosis. Outbreaks of pasteurellosis are frequently mistakenly diagnosed 
clinically as CBPP and visa versa (personal field observation). It is important to understand 
that in Somalia and in other African countries that CBPP and Pasteurellosis are almost 
always associated with each other and that differential diagnosis is important using 
serology before any conclusions are reached about the nature of the outbreak.
It is however necessary to point out that this assay should be employed in 
especial situations such as disputes arising from export animals and in areas where the 
disease has been declared eradicated and unclassifiable mycoplasmas by conventional 
methods are isolated.
While primers that can specifically detect M. mycoides subsp. mycoides DNA 
have been described, a PCR assay that can actually differentiate the virulent strains from 
the vaccine strain T1 has not been previously described. The advantages of having such an 
assay are:
(I). In field investigations where animals become infected after having been vaccinated: 
This is especially troublesome. It has been observed in animals infected with other 
infectious diseases and particularly with trypanosomiasis and other immunosuppressive 
diseases. The assay can verify from 120 pg of DNA for virulent strains and 80 pg of DNA 
for the T1 vaccine strain whether the clinical infections were due to the vaccine strain T1 
or a virulent strain or whether the outbreak was wrongly attributed to CBPP but was in fact 
another CBPP-like syndrome.
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(2). When exported animals are shown to have become diseased en route or upon arrival 
at their destination with a CBPP-like disease and to be excreting the organism culturally, 
the assay will be definitive in determining whether the culture isolates are in fact a virulent 
strain or the T1 vaccine strain.
(3). Vaccination against CBPP in animals incubating the disease or are in the subacute 
phase of the disease where serological and cultural detection are impossible, usually 
precipitates the disease fast, especially in outbreaks where some animals within the herd 
have already shown signs of the disease. The practice in Somalia of vaccinating all animals 
intended for export against CBPP may just bring about the above scenario. Under these 
circumstances, the PCR assay may be employed in screening all export-oriented animals
i
for the presence of M. mycoides subsp. mycoides “SC” type DNA from lung exudates 
clinically taken from the live animal. Any animal that tests positive can then be excluded 
from vaccination and thus from export and all appropriate actions can be taken against the 
herd from which the animal came if it is known.
(4). It takes few hours to obtain the results of the PCR assay when it takes days and 
sometimes weeks in cases of culturing to obtain results. In outbreak situations, time is a 
decisive factor. The sooner a definitive diagnosis is made, the faster preventive and 
containment measures can be taken.
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Some of the limitations of the multiplex PCR assay are:
(1). That it has limited use as a field diagnostic tool since it must be done in a well- 
equipped laboratory and have well-trained technicians to perform it.
(2). That we have not fully determined the specificity of the assay by testing it against other 
cattle mycoplasmas. These were not available at the time of this study.
The relatively high sensitivity and potential specificity of the PCR assay may 
have an impact on the export cattle in Somalia when disputes arise about mycoplasma 
isolations. In the case of the MP-V primer, a 160 bp sequence analysis comparison of the 
virulent Oremit strain and the vaccine T1 strain in the 458 fragment which the primer 
amplified in both strains revealed that they were similar and when compared to the 
sequences of the strains in Taylor et al, 1992 publication, it showed that both were similar 
to the strains Gladysdale, M. capricolum and F38. This fact may give this primer set a 
particular significance as specific for members of the M. mycoides cluster. Both the T1 and 
PG1 strains had identical sequence in this region when we compared the sequence of the 
458 bp fragment from both strains.
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Chapter 4. Guidelines for Collecting Representative Samples from the Nomadic
Population of Somalia
Introduction:
Since the economy of Somalia is largely dependent on the export of live 
animals and given the fact that these animals are vaccinated against CBPP prior to being 
exported, it has become problematic convincing the importing countries that any antibodies 
against M mycoides subsp. mycoides “SC” Type or viable organisms detected in these 
animals are a result of the vaccination with the T1 strain and not a result of natural infection 
with the virulent strain. What is therefore needed is to conduct a study in Somalia to assess 
the duration of vaccinal antibodies and the duration that T1 DNA can be detected from 
vaccinated animals. In such a study, we need to select representative herds and sample 
them regularly over a period of not less than 1 year utilizing serum samples, nasal and ear 
swabs, and most important, lung exudate samples obtained by inserting a sterile needle 
between the 5th and 6th intercoastal space and drawing about 5 ml of fluid. This study will 
also be utilized to establish the epidemiological sensitivity and specificity of the assay by 
collecting samples from the vaccinated animals, known naturally infected animals and 
animals that has never been exposed to infection or vaccination and test them with the 
assay. Establishing the specificity of the assay will depend on the application. If the 
application is to detect vaccine strains, then known naturrally infected animals can be used 
for specificity. If the application is for confirmation of an infection, then specificity can be 
established by including animals that have never been exposed to the disease. The sample 
size can be determined by first surveying the animals to find the proportion with M.
70
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mycoides antibodies or DNA then establishing the required preicision in 95% of the time, 
the sample size can be calculated:
n=4pq/L2 where n=sample size, q=l-p and L=the required precision (Martin et al, 1987).
Knowing the problems that can hinder studies in nomadic populations, a 
special consideration will be given to the problems and obstacles that can be encountered 
in collecting samples from the nomadic population of Somalia. This will include some 
insights from the author’s long experience in dealing with a nomadic population.
The Nomadic population in general:
Nomads constitute about 70% of Somalia’s human population and own more 
than 95% of the country’s livestock estimated at around 42 million head (Livestock stats, 
MLFR, 1 988-89-After 7 years of civil war, my assumption is that at least 10 million 
animals may have perished from diseases, predators both human and animals). The rest of 
the livestock are owned by sedentary crop fanners who live in small farming communities 
in the inter-riverine area of the country.
This nomadic population and their livestock are characterized by constant 
seasonal movements in search of grazing and water. This movement involves crossing 
regional boundaries within the country and across international borders into neighboring 
countries. In the 2 dry seasons (July-September; January-March), almost the whole 
livestock population in the south congregates in the inter-riverine area and around the 
boreholes both in the south and north-central parts. In the 2 rainy seasons (April-June; 
October-December), the livestock disburses into the interior of the country. Although the
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nomads utilize the animals for their milk, meat and transportation, the production system 
is not market-oriented. This reduces their dependence on markets and accounts for their 
inaccessibility during much of the year.
Obstacles to sampling the Somali nomads:
(1). A major problem is that of tracking and locating the nomads and their herds especially 
during the 2 rainy seasons when they disperse into the interior of the country and where 
muddy roads limit accessibility. This is a serious setback for studies that require year-round 
sampling.
(2). Overcoming the mistrust of the nomads in relation to government-sponsored studies. 
This perceived mistrust is reinforced by the constant lack of feedback to the nomads about 
the findings of previous studies, either of information or benefits.
(3). Obtaining the necessary funds and equipment. Somali politicians have always been 
indifferent to research.
(4). Locating sentinel herds as they move through the interior and across international 
boundaries.
(5). If the study requires vaccinations such as the one we propose here, one of the major 
obstacles would be in maintaining the Cold chain infrastructure because of the lack of 
mobile field laboratories equipped with refrigerators and freezers.
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General factors to be considered in sampling the nomadic livestock 
population of Somalia before starting the vaccination study:
(1). The lack of knowledge of the breed, age and sex composition of the Somali livestock 
population.
(2). There is a significant difference in the prevalence of cattle diseases between the 
Southern and Central-Northern parts of the country. This is particularly true in the 
prevalence of such chronic diseases as trypanosomiasis. It is known that the response to 
vaccination between animals infected with trypanosomiasis, dermatophytosis, etc., and 
those not affected is significantly different (Chima et ai, 1986; Osiyemi et al, 1985). In 
Somalia, at one point it was estimated that about 8% of cattle in the south are infected with 
trypanosomiasis while the prevalence in the north was considered to be zero.
(3). Grazing and watering opportunities are not evenly distributed across the country. These 
are more abundant in the south than in the north-central parts. The state of nutrition is 
known to have an impact on an animal’s ability to adequately respond to vaccination.
(4). The optimum time of the year to vaccinate the animals for the study is another issue 
that requires much attention. It is known that vaccination stresses livestock. Vaccinating 
animals in the dry season when they are already stressed by movement and poor grazing 
can have unforeseen consequences. If the animals are vaccinated at the beginning of the 
rainy seasons, finding them for subsequent sampling is going to be difficult because of their 
dispersal into the inaccessible interior of the country.
(5). Animals under the age of two years and those over the age of ten years should be 
excluded from the study because the former are still passively immune to CBPP and the 
latter are not exported.
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Selection of the study herds:
Since herds in the south and central-north parts of the country will be different 
in many ways, it will be necessary to select a random sample of herds in both parts and 
estimate the herd composition in terms of breed, age, sex, disease status, etc.. Based on that 
information, then we can select the herds for the study. The sample analysis should be 
separate for the two parts of the country so that we will have more precision in generalizing 
the results from the southern herds to the south and vice versa.
Almost all the watering points in the inter-riverine area and almost all the 
boreholes in the country where animals congregate in the dry seasons for water are known. 
Constructing a list of them is quite possible thus creating a sampling frame. Clustering or 
stratifying the sampling frame on a regional basis is also feasible and probably desirable. 
A random sample of herds from each strata can then be selected. The herds can then be 
systematically sampled for the animals to be included in the study.
Finally, sampling of identified animals in the selected herds on a monthly basis 
might be the best approach statistically and also in minimizing the cost o f the study.
Suggested solutions:
(1). Select sentinel herds on the basis of accessibility and status of disease under 
investigation.
(2). There are things that an investigator can do to get the cooperation of the nomads in 
studies that require repeated sampling. Exploiting the fact that nomads revere their 
community religious leaders and in all instances heed their advice. Approaching these
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religious leaders has been successfully used by the author in previous studies. Another 
successful approach the author had employed is to provide drugs and treat the sick animals 
of the nomads participating in the study free of charge. Also providing individual feedback 
goes a long way in establishing trust between owners and the investigator.
(3). Availability of mobile laboratories, radios and Global Positioning Satellite (GPS) 
capability can make locating, sampling and testing of nomadic herds much more easier and 
less expensive.
(4). Initial pilot study may be useful in determining not only the herd composition of 
Somali cattle but also in collecting some data on movement, production, reproduction, etc.. 
It is also tempting to collect the data from sedentary herds especially if it is a rainy season 
but one has to keep in mind that any data collected from such herds is in no way 
representative of the Somali nomadic livestock population. This will give the investigators 
the opportunity to sort out initial problems and to get a feel of the more complex later 
situation.
(5). Institute a campaign of mass education of the nomadic population so that the benefits 
and side effects of vaccinating their animals can be explained by professionals. This will 
also help get the professionals to know more about the nomads and their life styles so that 
they and the professionals can work in harmony.




Two primer sets (MP-2 and MP-3) were designed from a region of the cytadherence 
gene PI of M. pneumoniae and the P140 of M. genitalium share absolute homology and 
used to detect homologous sequences in M. mycoides subsp. mycoides “SC” Type, the 
etiological agent of Contagious Bovine Pleupneumonia (CBPP). Both primer sets amplified 
the expected fragments in all the virulent strains of the organism, a 488 bp fragment by MP- 
2 and a 303 bp fragment by MP-3. The two primers did not however amplify the expected 
fragments in the vaccinal T1 strain of the organism. This suggested that there might be a 
PI-like cytadherence gene in the virulent strains and that the gene may be missing in the 
vaccine strain T1.
To eliminate the possibility that the two primer sets, MP-2 and MP-3 were unable to 
amplify the expected fragments from the T1 strain because of inhibiting substances in the 
DNA preparation and to ascertain its amplifiability, we designed a primer set, MP-V, from 
the CAP-21 gene insert sequence described by Taylor et al, 1992. The primer set was 
expected to amplify a 458 bp fragment in all members of the M. mycoides cluster. This 
primer set amplified the expected 458 bp fragment in all the virulent strains as well as 
several Tl vaccine strains. The primer set did not however amplify the fragment in the 
closely-related M. pneumoniae and M. genitalium. Therefore this primer set provided 
evidence that the Tl DNA was amplifiable and that the PI-like cytadherence gene may be 
partially or totally missing from the Tl vaccine strain. To further investigate the latter 
possibility, we compared the protein patterns of a virulent strain PG1 and that of the Tl
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vaccine strain. The two strains showed differences in several proteins including high, 
medium and low molecular weight proteins one of which could be the PI-like gene 
product.
A multiplex PCR assay was then developed using the MP-3 primer which amplifies 
a 303 bp fragment only in the virulent strains and the MP-V primer which amplifies a 458 
bp fragment in all strains both virulent and vaccine. The multiplex PCR assay amplified 
two fragments (a 303 bp and 458 bp) in the virulent strains but only one fragment (the 458 
bp) in the vaccine Tl strain. We used this multiplex PCR to test crudely prepared field 
samples from herds suspected of CBPP infection. These herds were previously vaccinated 
against CBPP with the Tl vaccine strain and later came down with what is thought to be 
a CBPP-like syndrome. The assay did not amplify the 458 bp fragment in M. pneumoniae 
and M. genitalium proving that both organisms do not belong to the M. mycoides cluster. 
We are therefore reporting here the development and characterization of a multiplex PCR 
assay that differentiates the virulent strains of M. mycoides subsp. mycoides “SC” Type 
from the vaccine Tl strain, originally a virulent strain attenuated through passaging.
The multiplex PCR assay performed with a high degree of sensitivity and specificity. 
The microbiological sensitivity was determined by establishing the least amount of DNA 
that the assay can detect while the specificity was performed on human mycoplasmas 
because we had no animal mycoplasmas to test the assay with. Both sensitivity and 
specificity need to be further characterized.
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Conclusions:
(1). The multiplex PCR differentiated the virulent strains of M. mycoides subsp. mycoides 
“SC” Type from the vaccine Tl strain with a high degree of sensitivity (up to 1:106 
dilution) in relation to the organisms tested against it and specificity (Mp and Mg). The 
ability of this assay to differentiate between these strains may have a profound impact on 
the economy of Somalia by demonstrating that mycoplasma isolations from previously 
vaccinated animals are in fact the Tl strain and not the virulent strains of the CBPP agent.
(2). The multiplex PCR assay can also be used to detect animals silently incubating the 
disease and chronic carriers. This early detection will make it possible to take preventive 
measures before large devastating outbreaks occur.
(3). The PCR technology is relatively easy to perform and most important is inexpensive. 
Therefore, we can recommend it to the laboratories of the developing countries for 
confirmatory diagnosis of diseases under control or eradicated when detected with other 
means such as serology. Besides, this assay can settle disputes arising from the 
interpretation of conventional methods of pathogen detection specially in Somali cattle 
exports.
(4). Since we were forbidden by law to import live organisms into the United States of 
mycoplasma strains, protein analysis was performed on ethanol-fixed cell lysates with 
uninterpretable results. We recommend that the protein pattern comparison of the strains 
be done in countries where the disease is endemic using freshly extracted proteins.
(5). Since we did not have the required samples to establish the epidemiological sensitivity 
and specificity of the multiplex polymerase chain reaction (PCR) assay, it is necessary to
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test the sentivity with vaccinated animals when the application is the differentiation of 
virulent strains from vaccine strains. If the application is detection of the virulent strains, 
then it is necessary to use animals that had been exposed to the disease.
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2 7 0  . 300
CTC ACC CCT CAA AAT CCC CCC CCS TCC CCC TTA CTC CCC CAC AAC ACC CCT AAC CCC ATC
L e u  T h r  C ly  C lu  A en P r o  C l y  A le  T r p  A le  L e u  V e l  A rq  A ep A sn  S e r  A le  L ye C ly  l i e
3 3 0  360
ACT CCC CCC AST CCC ACT CAA CAA ACC ACC TAT CAT CCC ACC CCA ACC CAA CCC CCT TTC
T h r  A le  C ly  S e r  C ly  S e r  C l n  C la  T h r  T h r  T y r  A ep  P r o  T h r  A rq  T h r  C lu  A le  A le  Leu
3 9 0  420
ACC CCA TCA ACC ACC TTT CCS TTA CCC CSC TAT CAC CTC CCC CCC CCC CCC TTA TAC CAC
T h r  A le  S e r  T h r  T h r  P h e  A le  L eu  A rq  A rq  T y r  A ep  L e u  A le  C ly  A rq  A le  Leu T y r  A sp
4 SO 480
CTC CAT TTT TCC AAC TTA AAC CCS CAA ACC CCC ACC CCC CAC CAA ACC CCC CAC ATC ACC
L e u  A sp  P he S e r  Lye L e u  A en  P ro  C ln  T h r  P r o  T h r  A r q  A sp  C ln  T h r  C ly  C ln  H e  T h r
5 1 0  540
TTT AAC CCC TTT CCC CCC TTT CCT TTC ACT CCC CCT CCA CCC CAA CAC TCA AAC CAC CTC
P h e  A sn  P ro  Phe C ly  C ly  P h e  C ly  L eu  S e r  C ly  A le  A le  P ro  C ln  C ln  T rp  A sn C lu  V e l
5 7 0  600
AAA AAC AAC CTC CCC CTC CAC CTS CCC CAA CAC CCC TCC AAT CCC TAC CCC TTT CCC GTT
L y s  A sn  L ys V e l P ro  V e l  C lu  V e l A le  C ln  A sp  P r o  S e r  A sn  P ro  T y r  A rq  P he A le  V e l
6 3 0  6 60
TTA CTC CTC CCC CSC ACC CTC CTS TAC TAT CAC CAC TTC CAA ACC CCC TTC CCC TTA CCA
L e u  L eu  V e l P ro  A rq  S e r  V e l  v e l  T y r  T y r  C lu  C l n  L eu  C ln  A rq  C ly  Leu C ly  Leu P ro
6 9 0  720
CAC TAG CCA ACC CAC ACT CCT CAA AAT ACT TCC ACC ACC CCC CCA ATC TTT CCC TTC AAC
C l n  C l a  A rq  T h r  C lu  S e r  C ly  C ln  A sn  T h r  S e r  T h r  T h r  C ly  A le  M et P he C ly  Leu L ys
7 5 0  780
CTS AAC AAC CCC CAC CCC CAC ACC CCC AAC ACC AAT CAA AAA CTC CAC CCC CCT CAC CCC
v e l  L y s  A sn A le  C lu  A le  A sp  T h r  A le  L ys S e r  A sn  C lu  L y s  Leu C ln  C ly  A le  C lu  A le
8 1 0  1 4 0
ACT CCT TCT TCA A(fc ACA TCT CCA TCT CCC CAA TCC ACC CAA CCT CCC CCT TCC TCA CCC
T h r  C ly  S e r  S e r  T h r  T h r  SeV  C ly  S e r  C ly  C ln  S e r  T h r  C ln  A rq  C ly  C ly  S e r  S e r  C ly
8 7 0  9 00
CAC ACC AAA CTC AAC CCT TTA AAA ATA CAC CTC AAA AAC AAA TCC CAC TCC CAC CAC AAT
A sp  T h r  L ys V e l Lys A le  L eu  Lys l i e  C lu  V e l  L y s  L y e  L y s  S e r  A sp  S e r  C lu  A sp A sn
9 3 0  9 6 0
CCT CAC CTC CAC TTA CAA AAA AAT CAT CTC CCC AAC CCT CCC ATT AAC CCC ACC CAC CAC
C l y  C ln  L eu  G in  Leu C lu  L y s  A sn A sp  L eu  A le  A sn  A le  P r o  H e  L y s  A rq  S e r  C lu  C lu
9 9 0  102 0
TCC CCT CAC TCC CTC CAA CTC AAC CCC CAC CAT TTT CCT ACT CCC CTT TCC ACT TCC CCA
S e r  C l y  C ln  S e r  V e l C ln  L eu  L ys A le  A sp  A sp  P h e  C l y  T h r  A le  L eu  S e r  S e r  S e r  C ly
1 0 5 0  1080
TCA CCC CCC AAC TCC AAT CCC CCT TCC CCC ACC CCC TCA ACC CCC TCC CTT CCC ACT CAC
S e r  C ly  C ly  Aen S e r  A sn  P r o  C ly  S e r  P r o  T h r  P r o  T r p  A rq  P r o  T r p  L eu  A le  T h r  C lu
1 1 1 0  114 0
CAA ATT CAC AAC CAC CTC CCC AAA TCA TCC CCC TCC ATC CTC ATT CTC TAC CAT CCC CCT
C l n  Z l e  K is  L ys A sp  L eu  P r o  L ys T r p  S e r  A le  S e r  Z l e  L e u  H e  L eu  T y r  A sp  A le  P ro
1 1 7 0  1 2 0 0
TAT CCC CCC AAC CCT ACC CCC ATT CAC CCC CTT CAT CAC TTC CAT CCC AAC CCC ATC ACC
T y r  A le  A rq  A sn A rq  T h r  A le  Z le  A sp  A rq  V e l  A sp  H i s  L eu  A sp  P r o  L y s  A le  M et T h r
89
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1 2 1 0  1263
CCS AAC TAT CCC CCC AST TCA ASA ACS CCC AAC TCA AAC CAC CAC CCT TTC TCC CAC TCA
A la  A sn  T y r  P r o  P r o  S « r  T r p  A rg  T h r  P r o  L y s  T r p  A sn H is  H is  C ly  L su  T rp  A sp T rp
1 2 9 3  1320
AAC CCS CSC CAT CTT TTC CTC CAA ACC ACC CCS TTC TTC AAC CCS CCC CSC CAC CCC CAC
L ys A l t  A rc  A sp  V s l  L s u  L o u  C ln  T h r  T h r  C l y  Pho Phs A sn  P ro  A rg  A rg  K is  P ro  C lu
1 3 5 0  1363
T5S TTT CAT CCC CCS CAS ACC CTC CCS CAT AAC CAA AAC ACC CCC TTT CAT CTC CAT AAC
T rp  P h s  A sp  C ly  C ly  s i n  T h r  V s l  A l s  A sp  A sn  C lu  Lys T h r  C ly  P h s  A sp  V s l  A sp A sn
1 * 1 0  i « « 0
TIT  3AA AAC ACC AAC CAC CCC TTT CAA AAC CAA CCT CAC TCC CAC AAC TCS CCC CCC ATC
l » r  C lu  A sn  T h r  l y s  S i n  C ly  P n s  C ln  l y s  C lu  A ls  Asp S s r  A sp  L y s  S s r  A ls  P ro  I l s
1 * 9 0  1500
CCC CTC CCC TTT CAA, CCS TAC TTC CCC AAC ATT CCC AAC CTC ACC TCC TTC CCC CAA CCC
A ls  Lou P r o  P h s  C l u  A l s  T y r ,  P h s  A ls  A sn  I l s  C ly  Asn L su  T h r  T r p  P h s  C ly  C ln  A ls
1 5 3 0  156 0
CTT TTC CTC TTT CCT CCC AAT CCC CAT CTT ACC AAC TCS CCC CAC ACC CCS CCT TTC ACT
l s u  L su  V s l  P h s  C ly  C l y  A sn  C ly  K is  V s l  T h r  L ys S s r  A ls  K is  T h r  A ls  P r o  L su  S s r
1 5 9 0  162 0
ATA CCT CTC TTT ACC CTS CCC TAT AAT CCA ACT CCT ACC ACT CCT ACT CTA ACT CCT TCA
I l s  C ly  v s l  P h s  APT v s l  A rg  T y r  A sn  A l s  T h r  C ly  T h r  S s r  A ls  T n r  V s l  T h r  C ly  T rp
1 6 5 0  16*0
CCA TAT CCC TTA CTC TTC TCA CCC ATC C TS AAC AAA CAA ACT CAC CCS TTA AAC CAT CTA
P r o  T y r  A ls  L su  l s u  P h s  S s r  C ly  K s t  V s l  A sn  L y s  C ln  T h r  A sp C ly  L su  L y s  A sp  L su
1 7 1 0  1 740
CCC TTT AAC AAT AAC CSC TCC TTT CAA TAT CTA CCA CCS ATC CCA CTT CCT CCC CCT AAC
P r o  P h s  A sn  A sn  A sn  A rg  T r p  P n s  C lu  T y r  V s l  P ro  A rg H sc  A ls  V s l  A ls  C ly  A ls  L ys
1 7 7 0  H 0 0
TTC CTT CCT ACS CAA CTC CTT TTA CCS CCT ACC ATT ACC ATC CCT CAT ACC CCT ACC CTA
P h s  V s l  c l y  A rg  C lu  L s u  V s l  L su  A l s  C l y  T h r  I l s  T h r  K s t  c l y  A sp  T h r  A ls  T h r  V s l
1 * 3 3  1660
CCT CCC TTA CTC TAC SAT CAA CTT CAA ACC AAC CTC AAC TTA CTA CCC CAA CCC CAA CCT
P r o  A rg  L su  L su  T y r  A sp  C lu  l s u  C lu  S s r  A sn  L su  A sn L su  V s l  A ls  C ln  C ly  C ln  C ly
1 * 9 0  1920
CTT TTA CCC CAA CAC TTC CAA CTC TTC ACA CCC TAC CCA TCA CCC AAT CCT CCC CAT TTA
l s u  L su  A rg  C lu  A sp  l s u  C ln  L su  P h s  T h r  P r o  T y r  C ly  T rp  A ls  A sn  A rg  P ro  A sp L su
1 9 5 0  1 9*0
CCA ATC CSC CCT TCA ACT ACT AST ACT AST ACT ACT CAC AAC CCA CCC TAC TAC TTC CAC
P r o  I l s  C ly  A ls  T r p  S s r  S s r  S s r  S s r  S s r  S s r  S s r  H is  A sn A ls  P r o  T y r  T y r  P h s  K is
2 0 1 0  2 0 *0
AAT AAC CCC CAT TCA CAA CAC CCT CCA ATC CAA AAT CTC CTT CAT CCC TTT ATT AAC CCC
A sn  A sr. P ro  A sp  T r p  C l n  A sp  A rg  P r o  I l s  C ln  A sn V s l V s l  A sp  A ls  P h s  I l s  L ys  P ro
2 0 7 0  2 1 0 0
TCA CAC CAC AAC AAC CCT AAC CAT CAT CCC AAA TAC ATC TAC CCT TAC CCT TAC ACT CCC
T r p  C lu  A sp  L y s  A sn  C l y  L y s  A sp  A sp  A l s  L y s  T y r  I l s  T y r  P ro  T y r  A rg  T y r  S s r  C ly
2 1 3 0  2 1 6 0
ATC TCA CCT TCA CAC CTA TAC AAC TCC TCC AAT AAC CTC ACT CAC CAA CCA TTA ACT CCT
K s t  T r ?  A ls  T r p  C ln  V s l  T y r  A sn  T r p  S s r  A sn  L ys L su  T h r  A sp  C ln  P r o  L su  S s r  A ls
2 1 9 0  2 2 2 0
CAC TTT CTC AAT CAS AAT CCT TAC CAA CCA AAC TCC TTC TTT CCT CCT ATT CTC AAT CCC
A sp  P h s  V s l  A sn  C lu  A sn  A ls  T y r  S i n  P r o  A sn  S s r  L su  P h s  A ls  A ls  I l s  L su  A sn P ro
2 2 5 0  2 2 * 0
CAA TTC TTA CCA CCT CTT CCC CAC AAC CTT AAA TAC CCT AAC CAA AAC CAC TTT CCT CCT
C lu  L su  L su  A ls  A ls  L s u  P r o  A sp  L y s  V s l  L y s  T y r  C ly  L ys C lu  A sn  C lu  P h s  A ls  A ls
2 3 1 0  2 3 * 0
AAC CAC TAC CAC CCC TTT AAC CAS AAC TTA ACC CTA CCT CCT ACC CAA CCA ACA AAC TCA
A sn  C lu  T y r  C lu  A rg  P n s  A sn  C ln  L y s  L s u  T h r  V s l  A ls  P r o  T h r  C ln  C ly  T h r  A sn T r p
2 3 7 0  2 « o o
TCC CAC TTC TCC CCC ACC CTT TCC CCT TTC TCC ACC CCC TTC AAC CTT CTC CCC TCC CTC
S s r  H i*  P h s  S s r  P r o  T h r  L s u  S s r  A rg  P h s  S s r  T h r  C ly  P h s  A sn  L su  v * l  c l y  S s r  V s l
2 * 3 0  2 4 6 0
CTC CAC CAC CTC TTC CAT TAT CTC CCC TCC ATT CCC AAT CCC TAC ACC TAT CCC AAT AAC
L s u  A sp  C ln  v s l  L s u  A sp  T y r  V s l  P r o  T r p  I l s  C ly  A sn C ly  T y r  A rg  T y r  C ly  A sn A sn
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2 4 * 0  2 5 2 0
CAC CSC CCC CTC CAT CAT ATA ACC CCC CCT CAA ACC ACC CCC CCC TCC TCC ACC CCA ATT
K is  A rq  C l y  V s l  A sp  A sp  I l s  T h r  A ls  P r o  C l n  T h r  S s r  A l s  C l y  S s r  S s r  S s r  C ly  I l s
2 5 5 0  2 5 2 0
ACT ACC AAC ACA ACT CCT TCC CCT TCC TT T CTC CCC ACC TTT TCC AAC ATC CCC CTC CCC 
S s r  T h r  A sn  T h r  S s r  C ly  S s r  A rq  S s r  P h s  L s u  P ro  T h r  P h s  S s r  A sn  I l s  C ly  V s l  C ly
2 S 1 0  2 * 4 0
CTC AAA CCC AAT CTC CAA CCC ACC CTC CCS CCC ACT CAC ACC ATC ATT ACA CSC CCT TCC
L s u  L y s  A ls  A sn  V s l  C ln  A l t  T h r  L s u  C ly  C ly  S s r  C ln  T h r  H s t  I l s  T h r  C ly  C ly  S s r
2 6 7 0  2 7 0 0
CCT CCA ACA ACC CTC CAC CAA CCC AAC CTC CAC CTC TCA ACC CCC CCC CCS TCA ACC AAT
P r o  A rq  A rq  T h r  L su  A sp  C ln  A ls  A sn  L s u  C ln  L s u  T r p  T h r  C ly  A l s  C ly  T rp  A rq  A sn
2 7 3 0  276 0
CAT AAC CCT TCA ACT CCA CAA ACT CAC CAA AAC CAC ACC AAC TTC ACC ACC CCT ACC CCC
A sp  L y s  A ls  S s r  S s r  C ly  C ln  S s r  A sp  c l u  A sn  M is  T h r  L y s  P h s  T h r  S s r  A ls  T h r  C ly
2 7 9 0  2 * 2 0
ATC CAC CAC CAC CCA CAA TCA CCT ACC TCC CCC CCC AAT CCC CAC TCC TTA AAC CAC CAT
H a t  A sp  C l n  C ln  C ly  C ln  S s r  C ly  T h r  S s r  A l s  C ly  A sn  P r o  A sp  S s r  L s u  Lys C ln  A sp
2 * 5 0  2 * * 0
AAT ATT ACT AAC ACT CCC CAT ACT TTA ACC ACC CAC CAC CCC AAT CCC ATC CAT CAA CAA
A sn  l i e  S s r  L y s  S e r  C ly  Asp S s r  L su  T h r  T h r  C ln  A sp  C ly  A sn  A l s  I l s  Asp C ln  C ln
2 9 1 0  294 0
SAC CCC ACC AAC TAC ACC AAC CTC CCC CCC AAC CTC ACC CCC ACC CCT CAT TCA CCC AAC
C l u  A l s  T h r  A sn  T y r  T h r  A sn L su  P ro  P r o  A sn  L su  T h r  P r o  T h r  A l s  A sp  T rp  P ro  A sn
2 9 7 0  300 0
CCS CTC TCA TTC ACC AAC AAC AAC AAC CCC CAC CCC CCC CAC CTC TTC CTC CSC CCC TTC
A la  L su  S e r  P h s  T h r  A sn  Lys A sn A sn  A l s  C ln  A rq  A la  C ln  L s u  P n s  L su  A rq C ly  L su
3 0 3 0  3 0 (0
TTC CCC ACC ATC CCC CTC TTC CTC AAT CCA ACT CCC TCC CAT TCC AAC AAA TTC CAA CCC
L s u  C ly  S s r  I l s  P r o  V s l  L su  V s l A sn  A rq  S s r  C l y  S s r  A ap  S s r  A sn  L ys Phs C ln  A ls
3 0 9 0  ’ 312 0
ACC CAC CAA AAA TCC TCC TAC ACC CAC TTA CAT TCC CAC CAA ACC AAA CTC AAC CTC CCC
T h r  A sp  C ln  L y s  T r p  S s r  T y r  T h r  A sp  L s u  K i s  S s r  A sp  C ln  T h r  L y s  L su  Aqn L su  P ro
3 1 5 0  3 l« o
CCT TAC CCT CAC CTC AAT CCC TTC TTC AAT CCC CCC TTC CTC CAA ACC TAT TTT CCC AAC 
A la  T y r  C ly  C lu  V a l  A sn  c l y  Lsu L su  A sn  P r o  A la  L su  V s l  C lu  T n r  T y r  P hs C ly  A sh
2 2 1 0  3240
ACC CCA CCS CCT CCT TCC CCC TCC AAC ACC ACC ACT TCA CCC CCT ATC CCT TTT AAA ATT
T h r  A rq  A la  C ly  C ly  S s r  C ly  S s r  A sn  T h r  T h r  S s r  S s r  P r o  C ly  I l s  C ly  P hs L ys I l s
3 2 7 0  33 0 0
CCC CAA CAA AAT AAT CAT TCC AAA CCC ACC CTC ATC ACC CCC CCC TTC CCT TCA ACC CCC 
P r o  C lu  C ln  A sn  A sn  A sp  S s r  Lys A ls  T h r  L s u  I l s  T h r  P r o  C ly  L s u  A la  T rp  T h r  P ro
3 3 3 0  336 0
CAC CAC CTC CCT AAC CTC CTT CTC ACT CCC ACC ACC CTC ACC TTC CAC CTC CCC CCC TCC 
C ln  A sp  V a l  C ly  A s n ’ L eu  V s l  V s l S s r  C l y  T h r  T h r  V a l  S s r  P h s  C l n  L su  C ly  C ly  T rp
3 3 9 0  342 0
CTC CTC ACC TTC ACC CAC TTT CTC AAA CCC CCC CCC CCT TAC CTC CCT CTC CAC TTA ACC 
L su  V a l  T h r  P h s  T h r  A sp  P hs V s l  L y s  P r o  A rq  A la  C ly  T y r  L su  C l y  L s u  C ln  L su  T h r
3 4 5 0  3 4 (0
CCC TTC CAT CCA ACT CAT CCS ACS CAC CCC CCC CTC ATT TCC CCC CCC CCC CCC TCA CCC 
C ly  L s u  A sp  A la  S s r  A sp  A la  T h r  C ln  A rq  A la  L s u  I l s  T r p  A la  P r o  A rq  P ro  T rp  A la
3 5 1 0  3540
CCC TTT CCT CCC ACT TCC CTC AAC CSC TTC CCC CCC CTC CAC ACT CTC TCC CAT TTC AAC 
A la  P h s  A rq  C ly  S s r  T r p  V a l A sn A rq  L s u  C ly  A rq  V a l  C lu  S s r  V a l  T r p  A sp L su  L ys
3 5 7 0  360 0
CCC CTC TCC CCC CAT CAA CCT CAC TCC CAC TCC CAA CCA TCT ACC ACC ACC CCA ACA ACC 
C ly  V a l  T r p  A la  A sp  C ln  A la  C ln  S s r  A sp  S s r  C ln  C ly  S s r  T h r  T h r  T h r  A la  T h r  A rq
3 6 3 0  366 0
AAC CCC TTA CCC CAC CAC CCC AAT CCT TTC CCC TTT CAC CTC ACT CTC CTC CAA CCC ACT 
A sn  A la  L su  P r o  C lu  H is  P ro  A sn A la  L s u  A la  P h s  C ln  V a l  S s r  V a l  V a l  C lu  A la  S s r
3 6 9 0  372 0
CCT TAC AAC CCA AAC ACC ACC TCC CCC CAA ACC CAA TCC ACT AAC ACT TCC CCC TAC CTC 
A la  T y r  L ys P r o  A sn  T h r  S s r  S s r  S l y  C ln  T h r  C ln  S s r  T h r  A sn  S s r  S s r  P ro  T y r  L su
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
92
J ? S C
CAC TTC CTS AAC CCT AAC AAA CTT ACC CAA
H is  L eu  V a l L ys  P ro  L y s  L y s  V a l T h r  C l n
3 H 0
CTC TTC CAC CCC AAC CAC CTT CSC ACC AAC
l e u  L eu  A sp P ro  A sn  C ln  V a l  A rg  T h r  L y s
3 1 7 0
ACC CAC CCC CAC CCC CAA TCC CTC AAA ACA
T h r  C ln  P ro  C ln  P r o  C ln  S a r  Leu L y s  T h r
393C
AAC CTC AST ACT CTC CTT ACT CCT CSC CCT
A sn L eu S a r  S a r  V a l  L eu S e r  C ly  C ly  C ly
3 9 9 0
TCT CCC CTC CAT CTC TCC CCC CTT CAA AAA
S e r  C ly  V a l  A sp  Leu* S a r  P r o  V a>  C lu  L y s
4 0 5 3
ACC ACC ACT CAC CCA AAC ACC TCC TCC ACC
S a r  T J ir  S a r  A sp C ly  A sn T h r  S e r  S a r  T h r
4 1 1 0
AAT CAT CTC CTC CCC CTT CCT CCA CTT TCT 
A sn  A sp  V a l V a l C ly  V a l C ly  A rq  L eu  S e r
4 1 7 0
CTT CAT CCT ATT CTA CCC ACC CCA CTC CCT 
V a l A sp  C ly  H e  V a l  A rq  T h r  P ro  L eu  A la
4 2 3 0
CAC ACT CCT CCA CAA ACC CTC AAC TTC AAC 
A sp T h r  C ly  P ro  C ln  S e r  V a l  Lya P h e  L y s
4 2 9 0
TTT ACC CAC CCA CTC ACC CAT CTC TTT CAT 
P he T h r  K is  P ro  V a l  T h r  A sp  Leu P he A sp
4 3 5 0
ATA CCC CTC TTT ATT CAT ATC CCA CCA ACT 
H e  P r o  Leu P he l i e  A sp  l i e  P ro  A la  S e r
4 4 1 3
TTC ACC TTT CAC ACC AAC CAA CAC ACC TTA 
Leu S e r  P he A sp T h r  A sn C lu  C ln  S e r  L e u
4 4 7 0
CAA CAT ACC CAA CCA AAC AAC AAC CTT CAC 
S in  A sp  T h r  C ln  P r o  A sn  A sh  A sn V a l  C ln
4 5 3 0
CTS TTA ACC CCC TCC ACT CAA CCT CCC CAA 
Leu L e u  T h r  A la  S e r  S e r  C ln  C ly  P ro  C ln
4 5 9 0
CAT TAC CTC TTC CCC TTA CCC ATC ACT CTA 
A sp  T y r  V a l L eu  P r o  L eu A la  Z le  T h r  v a l
4 5 5 0
TTA CCA CTT CCC ATT CCA ATC CCA ATC CAC 
L eu C ly  Leu A la  t i e  C ly  l i e  P ro  K ec  K i s
4 7 1 0
CCC CTA TCA AAC CAA AAC CTT CAT CTC TTC 
A la  L eu  S e r  A sn  C ln  L y s  V a l  A sp  V a l L e u
4 7 7 0
ATC ATT AAC CSC ACA CCT ATC ACT CAA CCS 
Z le  l i e  A sn  A rg  T h r  C ly  Z l e  S e r  C ln  A la
4 1 3 0
AAA CCA CCA CCA CCC CCC CCA CCA CTA CCA 
L ys P r o  C ly  A la  P r o  A rg  P ro  P ro  V a l  P r o
3 7 1 0
TTC CAC AAC TTA CAC SAC SAT CTT AAA AAC
S e r  A sp  L y s  L eu  A sp A sp  A sp  Leu Lys A sn
3 1 4 0
CTS CCC CAA ACC TTT CCT ACA CAC CAT TCC
L e u  A rg  C ln  S e r  Phe C ly  T h r  Asp K is  S e r
3 9 0 0
ATC ACA CCC CTA TTT CCC ACC ACT ACT CCT
T h r  T h r  P ro  V a l Pha C ly  T h r  S a r  S a r  C ly
3960
CCT CCA CCC CCT TCT TCA CCC TCA CCT CJUl
A la  C ly  C ly  C ly  S a r  S a r  C ly  S a r  C ly  C ln
4 0 2 0
CTC ACT CCC TCC CTT CTC CCC CAC TTA CCA
V a l  S e r  C ly  T rp  Lau V a l C ly  C ln  Leu P ro
4 0 1 0
AAC AAC CTC CCS CCT AAT ACT AAT ACC CCC
A sn  A sn  Lau A la  P ro  A sn  T h r  Asn T h r  C ly
4 1 4 0
CAA ACC AAC CCC CCA AAC ATS AAT SAC CAT
C lu  S e r  A sn  A la  A la  Lya K ec Aen Aap A sp
4 2 0 0
CAA CTC TTA CAT CCC CAA CCA CAA ACA CCT
C lu  L eu  L eu A sp C ly  C lu  c l y  C ln  T h r  A la
4 2 6 0
TCT CCT CAC CAA ATT CAC TTC AAC CCC TTC
S e r  P r o  A sp C ln  H e  A sp P ha A sn A rg Leu
4 3 2 0
CCS CTA ACT ATC TTC CTC TAT CAC CAC TAC
P r o  V a i  T h r  K ec Leu V a l T y r  A sp C ln  T y r
4 3 1 0
CTC AAC CCT AAA ATC CTT CCT TTA AAC CTC
V a l  A sn  P ro  Lys H a t  V a l A rg  Lau Lys V a l
4 4 4 0
CCT CTC CCC TTA CAC TTC TTT AAA CCT CAT
S l y  L e u  A rg  Leu C lu  P ha P h e  L ys Pr.o A sp
4 5 0 0
CTC AAT CCC AAT AAC CCT SAC TTC TTA CCA
V a l  A sn  P ro  A sn A sn C ly  A sp  P he Leu P ro
4 5 6 0
ACC TTC TTT ACT CCC TTT AAC CAC TCA CCT
T h r  L e u  P h e  S e r  P ro  p h e  A sn  C ln  T rp  P ro
CCT ATT CTT CTC ATT CTC CTC ACT CTT ACC
P r o  Z l e  V s l  V a l H e  V a l L au  S a r  V a l T h r
4 6 1 0
AAC AAC AAA CAC CCC TTC AAC CCT CCC TTT
L y s  A sn  L ya c l n  A la  L eu  L y s  A la  C ly  Phe
4 7 4 0
ACC AAA CCC CTT CCT ACT CTC TTT AAC CAA
T h r  L y s  A la  V a l C ly  S e r  V a l  P he L y i C lu
4 1 0 0
CCA AAA CCC TTC AAA CAA ACC ACT CCC CCT
P r o  L y s  A rg  Leu L ys C ln  T h r  S e r  A la  A la
4 1 6 0
CCA AAC CCA CCC CCT CCT AAC CCA CCA CTC
P r o  L y s  P r o  C ly  A la  P r o  L ys P ro  P ro  V a l
CAA CCA CCT AAA AAA CCC CCT TACTATTTATSAAATCCAACCTAAACTTAAAACCTTATTTACTCT 1 1 1 TAC 
C ln  P r o  P ro  L ye L y s  P r o  A la  End • •  • •  ' • •  •
c a c t t t t a c c c c t a g c a c g t t c t c a c t a g c c a a c a c c t a c c t c c t c c a a c a c c a c a a c a c c c t c a c c c c c t a c a o g c c c












10 20 30 <10 50 ■ 60 70 00 90 IOC
CAP TTCrCAAGGACGVrCACTATATGCAGTAAA/\AOiAr;e - AAAACT 1‘AAAAAA TAATAAATCAAAT..............I'A • ATAAGTl IT - CTATATGAA - - -riV LV iA A l.
YGO VrCTCAACGACGTl'CCCTATATCCACTAAAAACACCTAAAACTTAAAAAA TAATAAATCAAAT..............TAAATAAOTTT- GTATATGAA- - -TTAA3AAL
GLA TTCTCAACGACCTTCACTATATCCAGTAAAAAGACC - AAAAGTTAAAAAA TAATAAA'l’C AAAT..............TA - ATAAGTGT - GT ATATGAA 1TAA0AAG
BG7 TTCACAACGACCTrCATTATATGGAGTAAAAAGACCT- AAAGTT AAAA AA T  AAC AAAATAAATAGT AAT AAAT AAACCGTGTATATCAA - - A1TAAAAAC
KID TTCACAAGGACGTrCATTATATGGAGTAAAAACACCT-AAAGTl AAAAAA TAATAAAACAAA'VAA'VAAGTAAACCGT GTATATCAA- -A1TAAAAAG
F3 0 Tl'CACAAGGACGTTCATVATATGGAGTAAAAAAACCT- AAAGTTAAAAAA TAATAAAACAAATAATAATAAGTAAACCCTCTATATCTCAAATTAAA-LAG






F3 8 AACACATTAA--GTAGCATATTTATATTAAAAAGAAACGAG'lTATrACCA TGCGTAAGAATAGAGCAGAAAAAAGAGATGTm’AGCACATCCAATTTAT
v£>
G J
2 1 0  2 2 0  2 3 0  210  2 5 0  2 6 0  270 2 0 0  2 9 0  230
CAP AATTCTAAATTAGTTACTCGTCCAATTAATAAAATrATCTTAGATCGTAA AAGAGGAATTGCTCAGTCAVlTATTrATGA'I'GCATrTAATATAATTAAAC 
YGO AATTCTAAA1TAGTTACTCGTGCAATTAATAAAATTATGTTAGATGGTAA AAGAGG AATl’GCTCAGTC AATT ATTTATGA’l'CCATTT AAT AT AATT AAAG
GLA AATTCTAAATTAGTTACTCGTGCAATTAACAAAATT ATGTr AGATGGTAA AAGAGGAATT-C - - -GTCAATrATTTATCATCCATTTAATATAATTAAAG
BG7 AATTCTAAATTAGTTACTCGTGCAATTAATAAAATTATGTTAGATGGTAA AACAGGAATTCCTCAG7CAA1TATTTATGATCCATTTAATATAATTAAAC
KID AATTCTAAATTAGTTACTCGTGC AATT AATAAAA TTATGTTAGATGGTAA AAGAGG AATTGCTCAGTC AATTATTTATGATCC ATTTAATATAATT AAAC
F3 8 AATTCTAAATTAGTTACTCGTGC AATT AATAAAATTATGTTAGATGGTAA AACACGAATrGCTC ACTCAATrATTTATGATCCATTTAATATAATTAAAG
310  320  3 3 0  340 350  360  370 300  390 C O
CAP AAAAAACTAATAAAGAACCAATTGAACTATTTAATAAACCTATTCAAAAT ATTAAACCTCACTTAGAATrAAAAGTTCGTCGTATTGGACGAGCTAAC7A 
YCO AAAAAACTAATAAACAACCAATTGAAGTATT7AATAAACCTA1TGAAAAT ATTAAACCTCACTTAGAATTAAAAGITCGTCGTATTCGACGAGCTAACTA 
CLA AAAAAACTAATAAAGAACCAATTGAAGTATTTAATAAACCTA'ITi IAAAAT ATTAAACCTCACTTAGAATTAAAAGTTCGTCCTATTCGAGCACCTAAC7A 
BG7 AAAAAACTAATAAAGAACCAATTGAAGTA'nTAATAAAGCTATl’GAAAAT ATTAAACCICACITACAAVrAAAAGTTCGTCCTATTCGACGACCTAACTA 
KID AAAAAACTAATAAAGAACCAATTGAAGTATTTAATAAAGCTATIGA'aAAT ATTAAACCTCATTTAGAA1TAAAAGT7CGTCGTATTGCAGGAGCTAAC7A 
F3 8 AAAAAACTAATAAAGAACCAATTCAACTATTTAATAAAGC7AT1CAAAAT ATTAAACC'ICATlTAGAA'ITAAAAG'rTCGTCCTAlTCGACGACCTAAC'TA
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EG 7 TCAAGTTCCTCTAGAAGTTTCACCTGAAAGACAAATCACTTTAGCTITAC GTTGATT AATT AATTA’IGCAAGATTAAGAAACGAAAAAGTTATGAC AATT
K ID  TCAAGTTCCTGTAGAAGTTTCAGCTGAAAGACAAATCACTTTAGCTTTAC CTTGATTAATTAATTATCGAAGATTAAGAAACGAAAAAGTTATGACAATT
F3 8 TCAAGTTCCTGTAGAAGTTTCAGCTGAAAGACAAATCACTTTAGCTTTAC GTTGATTAATTAATTATGCAAGATTAAGAAACGAAAAAGTTATGACAATT
510 520  5 3 0  540 550 560 570  580 590  600
CAP AAATTAGCTAATGAAATTATTGATCGATCAAATAATATTGGTGGATCAGT TAAAAAACGTGAAGATACTCATAAAATGGCAGAACGAAATAAAGCGTTTG 
YGO AAATTAGCTAATGAAATT ATTGATGC ATC AAAT AAT ATTGGTGGATCAGT TAAAAAACGTGAACATACTCATAAAATGGCACAAGCAAATAAAGCGTTTG 
GLA AAATGAGCTAATGAAATTATTGATGCATCAAATAATATTGGTGGATCAGT TAAAAAACGTGAAGATACTCATAAAATGGCACAACCAAATAAAGCGTTTG 
BG7 AAATTAGCTAATGAAATTATTGATGCATCAAATAATATTGGTGGATCAGT TAAAAAACCTGAAGATACTCATAAAATGGCACAAGCAAATAAAGCATTTG 
KID AAATTAGCTAATGAAATTATTGATGCATCAAATAATTTTGGTGGATCAGT TAAAAAACGTGAAGATACTCATAAAATGGCAGAAGCAAACAAAGCATTTG 
F 3 8 AAATTAGCTAATGAAATTATTGATCGATCAAATAATATTGGTGGATCAGT TAAAAAACGTGAAGATACTCATAAAATGGCAGAAGCAAACAAAGCATTTG___ • _ M • *• *
6 1 0  620  6 3 0  640  650 660  670  6 8 0  690 7 0 0
CAP CTCATTATCGTTGATAATCAAA TTAGAAAGGAAAATAC-GAAA TGGCTAGAGAATACAGTTTATTAAATACTCGTAATATTGGTATTATGGCT
YGO CTCATTATCGTTGATAATCAAA TTAGAAAGGAAAATAC-GAAA TGGCTAGAGAATACAGTTTATTAAATACTCGTAATATTGGTATVATGGCT
GLA CACACTATCGTTGATAATCAAA TTAGAAAGGAAAATAG-CAAA TGGCTAGAGAATACAGTTTATTAAATACTCCTAATATTGGTATTATGGCT
BG7 CACACTATCGTTGATA.......................... ...........TTAGAAAGGAAAATTAATAAA TGGCTAGAGAATACAGTTTATTAAATACTCGTAATATTGGTATTATGGCT
KID CACACTATCGTTGAT C - -  ATT -  AG AATTAGAAAGG AAAATT AATAAA TGGCTAGAGAATACAGTTTATTAAATACTCGTAATATTGGTATTATGGCT
F 3 8  CACACTATCGTTG- -A A T - -AATT AAG AATTAGAAAGG AAAATT AATAAA TGGCTAG AGAATAC AGTTTATTAAATAATCG AAATATT - CAATTATGGCT
•  •  •  • • • •  m m ft *
7 1 0  7 2 0  7 3 0  7 4 0  750  760  770  7 8 0  790  8 0 0




K ID  AATATTGATCCTGGTAAGACTACTACTACTGAACGTAT7T TATTTCACAC TGGAAAAA TTC ACA AAAT AGGTG AAAC ACATGAAGGTGCTTCACAAATGG
F38 CATATTGATGCTGGTAAGACTACTACTACTGAACGTATTTTATTTCACAC TGGAAAAATTCACAAAATACGTGAAACACATGAAGGTCCTTCACAAATCG 
•  •  •
sO
Appendix C:
Gel and buffers for the SDS-PAGE:
12% Seperating Gel:
Acrylamide (30%) 20 ml
dH20  16.75 ml
1.5M TRIS-HC1 pH 8.8 12.5 ml
10% SDS 500 fA




Acrylamide (30%) 1.3 ml
dH20  6.1 ml
0.5M TRIS-HCI pH 6.8 2.5 ml
10% SDS 100//I








0.5M TRIS-HC1 pH 6.8 1 ml
Glycerol 1.6 ml
10% SDS 1.6 ml
B-mercaptoethanol 0.4 ml
0.5% bromophenol blue 0.4 ml
Total 8 ml
b. Running Buffer
lOx SDS-TRIS-GIycine buffer (Bio-Rad) diluted to lx.
This was used both electrode buffer and running buffer.
C. Staining Solution:
40% Methyl alcohol 
10% Acetic acid 
0.1% Comassie blue
d. Destaining Solution:
40% Methyl alcohol 
10% Acetic acid
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